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CHAPTER 1 
 
INTRODUCTION AND SIGNIFICANCE 
 
1.1 Motivation 
In February 2001, two research groups led by Francis Collins and Craig Venter published a nearly 
complete sequence of the human genome [1, 2]. Their work was the culmination of the Human 
Genome Project (HGP)—a 13-year coordinated effort by a group of 32 scientists in 14 countries. 
One striking finding from the HGP is that only 1.5% of the approximately 30,000 genes in the 
human genome encodes for protein [3]. This is surprising because proteins are the most common 
organic molecules found in cells [4]. If DNA is an instruction manual, then proteins are the 
building blocks of life. What then is the point of the other 98.5% of our DNA? While the purpose 
of much of the genome remains a mystery, between 5–10% of DNA is transcribed into non-coding 
RNA [5, 6]. Non-coding RNA molecules are never translated into proteins, yet they are highly 
abundant and serve critical functions within all cells. Mutations and imbalances in one class of 
regulatory non-coding RNAs, known as microRNA (miRNA), correlate with development of 
diseases such as cancer and cardiovascular disease [7]. Inhibition of miRNA is a potentially potent 
therapeutic strategy because single miRNAs are known to regulate hundreds of different disease-
associated genes [8]. Consequently, there is a tremendous opportunity to develop a new class of 
therapeutics that can target and correct the expression of aberrant miRNA. 
One promising candidate for therapeutically inhibiting miRNA is a peptide nucleic acid 
(PNA). PNAs are synthetic nucleic acids wherein the negatively charged sugar-phosphate 
backbone is replaced with charge-neutral peptide bonds [9].  Nucleobases (A, C, T, and G) are 
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spaced along the peptide backbone such that PNA hybridization with DNA and RNA obeys the 
rules of Watson-Crick base pairing [10, 11]. PNA offer several advantages over DNA- and RNA-
based drugs, including greater binding affinity for target RNA molecules [12] and innate resistance 
to enzymatic degradation [13, 14]. These attributes make PNAs ideal candidates for application as 
anti-miRNA therapeutics [15]. 
Unfortunately, intravenously delivered PNA will exit a patient’s blood stream and clear 
their kidneys in under 5 min [16].  This short blood circulation half-life is due to PNA’s small size 
and neutral charge, which also prevent it from interacting with and entering into diseased cells 
[16]. Thus, potentially the biggest challenge in clinical translation of PNA therapies is achieving 
efficient biodistribution and activity in target tissue while minimizing side-effects in healthy tissue. 
To address this challenge, the field of material science turns to the tools of nanoscience— 
engineering materials at a scale one-billion times smaller than a meter to create devices for targeted 
delivery of the next generation of therapeutics. 
 
1.2 Approach 
This work focuses on engineering nanoparticle (NP) vectors to improve PNA delivery and anti-
miRNA activity in target cells [17]. Unlike isolated PNA, NPs can be tightly engineered to control 
stability in blood, uptake by cells, and PNA delivery to the cellular cytoplasm where miRNA 
targets are located [18-21]. Specifically, NPs made from porous silicon (PSi) are engineered to 
improve the intracellular delivery and anti-miRNA activity of therapeutic PNA. PSi is an ideal 
material for drug delivery because it is biocompatible, meaning that it is not harmful to living 
tissue [20], and biodegradable, meaning that PSi is eventually broken down by the body into non-
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toxic metabolites [22]. PSi possesses a large internal surface area for drug loading [23, 24] and can 
be fabricated into particles suited for intravenous drug delivery [18-20, 23, 25]. 
 As the core of the delivery construct, porous silicon nanoparticles (PSNPs) enable accurate 
particle distribution in the targeted tissue before the PSNPs degrade and release their PNA payload. 
PSNPs also serve a critical role as a scaffold for PNA loading. Negatively charged DNA and RNA-
based oligonucleotides are typically loaded into NPs by electrostatic interactions. Unmodified 
PNA is neutrally charged and cannot be loaded electrostatically into conventional nucleic acid 
delivery systems. In this work, the high internal surface area (>100 m2 cm-3)[26] and polar surface 
chemistry of oxidized PSNPs [27] are leveraged to enable a high degree of PNA loading. Finally, 
the surface of the drug-loaded particles is functionalized with a polymer that enhances PSNP 
stability in the blood and improves the PNA delivery to its site of action in the cell cytosol.  
This polymer, referred to as PEGDB, is composed of two blocks. The first block is 
hydrophilic poly[(ethylene glycol)] (PEG), the second consists of hydrophobic butyl methacrylate 
(B) and pH-responsive dimethylaminoethyl methacrylate (DMAEMA) [28]. PEGDB’s 
amphipathic and pH-responsive nature allows it to self-assemble on the surface of PSNPs. On the 
outermost surface of the PEGDB/PSNP nanocomposite, PEG enhances particle colloidal stability 
and decreases interaction with blood serum proteins. PEG therefore increases the circulation half-
life of the particles in blood.  When PNA-loaded nanocomposites reach target cells they are 
internalized by a process called endocytosis. During endocytosis, compartments known as 
endosomes gradually acidify as they attempt to break down the internalized particles. The pH-
responsive DB component of the nanocomposite takes advantage of this natural acidification 
process by disrupting endosomal membranes and triggering release of PNA into the cell cytosol. 
Thus, the combination of PSi and PEGDB improves the delivery and activity of PNA therapeutics. 
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1.3 Innovation 
There are currently no clinically-approved anti-miRNA therapeutics. PNA has shown tremendous 
therapeutic promise in vitro, but its clinical translation is stymied by a lack of delivery technologies 
suited for systemic administration in vivo. This work introduces a nanocomposite proven to 
overcome both systemic and intracellular barriers to anti-miRNA PNA delivery. The innovative 
use of PSi as a PNA loading scaffold resulted in the highest reported PNA loading of any 
nanoparticle system to date. Furthermore, the novel combination of PSi with an endosomalytic 
polymer yielded a composite material with enhanced stability in the blood and improved PNA 
delivery to its intracellular site of action. These novel nanocomposites can be used to tailor PNA 
dose, blood circulation half-life, release profile, and cell-permeability. PSi nanocomposites 
therefore allow greater control over PNA anti-miRNA pharmacokinetics than current PNA 
delivery technologies. Consequently, this delivery platform may aid the clinical translation of a 
valuable new class of therapeutics.  
 
 
1.4 Specific Aims 
This works’ central hypothesis is that PNA anti-miRNA activity can be improved by engineering 
PSNPs to increase PNA blood circulation half-life, cellular uptake, and intracellular delivery to 
the cytoplasm. This hypothesis will be evaluated through the completion of the following three 
specific aims: 
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Aim 1: Develop and assess strategies for loading PNA into PSi.  
Three different, non-electrostatic loading strategies will be developed and evaluated according to 
the degree of drug loading, purity of loaded PNA sequence, and control over PNA release. The 
effect of loading strategy on PNA bioactivity will be investigated in vitro in Huh7 human liver 
cancer cells using Luciferase as a bioluminescent reporter for anti-miRNA activity.  
 
Aim 2: Develop and assess the activity of PEGDB/PSNP nanocomposites in vitro.  
A method will be developed for coating PSNPs with pH-responsive PEGDB polymers (comprised 
of a hydrophilic polyethylene glycol (PEG) segment and a hydrophobic, pH-responsive, 
endosomalytic segment). The effect of the PEGDB polymer coating on particle stability in serum, 
cellular uptake, intracellular trafficking, and anti-miRNA activity will be assessed in Huh7 human 
liver cancer cells in vitro. 
 
Aim 3: Assess the activity of PNA-loaded PSNPs targeted against miR-122 in vivo.  
MiR-122 is a well-studied, liver-specific miRNA involved in cholesterol biosynthesis and 
Hepatitis C viremia [29]. PNA therapeutics validated against miR-122 will be delivered 
systemically to mice using both uncoated PSNPs and the PEGDB/PSNP nanocomposites 
developed in Aim 2. The biodistribution, pharmacokinetics, and toxicity of intravenously-
delivered PNA will be evaluated as a function of delivery platform. PNA anti-miRNA activity will 
then be evaluated by monitoring changes in the expression of miR-122, its downstream gene 
targets, and the concentration of plasma cholesterol in the blood. 
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1.5 Outline 
This dissertation describes the development and validation of a nanoparticle delivery vehicle for 
improved delivery of PNA anti-miRNA therapeutics. Chapter 2 will review how miRNA inhibition 
works, how PNA anti-miRNA design compares with other relevant oligonucleotides, and how 
PNA delivery barriers might be overcome using PSNPs. Chapter 3 compares strategies for loading 
PNA into PSi and details methods for fabricating PSNPs. Chapter 4 describes the development of 
PEGDB/PSNP nanocomposites and evaluates their ability to overcome intracellular barriers to in 
vitro PNA anti-miRNA activity. Chapter 4 then evaluates the effectiveness of PEGDB/PSNP 
nanocomposites at overcoming systemic delivery barriers to PNA anti-miRNA activity in vivo. 
Finally, a summary of the major results and a discussion of the broader impacts, challenges, and 
future directions for this work will conclude this dissertation. 
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CHAPTER 2 
 
BACKGROUND 
 
Text partially adapted from: 
Beavers KR, Nelson CE, Duvall CL. MiRNA Inhibition in Tissue Engineering and regenerative 
Medicine. Advanced Drug Delivery Reviews. 2015; 88: 123-137 
 
2.1 Therapeutic miRNA inhibition 
The body relies upon a complicated series of checks and balances to maintain homeostasis. 
Imbalances or malfunctions in this regulatory network commonly result in disease. MiRNA 
molecules are key players in this system of checks and balances because they regulate nearly all 
of the body’s fundamental processes [30]. MiRNA act by preventing translation of messenger 
RNA (mRNA) into protein [31]. Individual miRNA are often cross-reactive with hundreds of 
different mRNA [8]. As a result, miRNA can orchestrate comprehensive responses by affecting a 
broad network of related genes.   
Multiple stages during the biogenesis of miRNA represent potential points of intervention 
for anti-miRNA therapeutics (Figure 2.1). The first step in miRNA production is transcription into 
long primary RNA transcripts known as pri-miRNAs.  The pri-miRNAs are cleaved by Drosha in 
the nucleus into a 70 base pair pre-miRNA hairpin intermediate. Pre-miRNAs are then exported 
to the cytoplasm and processed by Dicer ribonucleases into mature, double-stranded miRNA that 
are between 18 and 25 nucleotides in length. The mature miRNA interacts with the proteins that 
comprise the RNA-induced silencing complex (RISC), which separates the guide strand of the 
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mature miRNA from the passenger strand—retaining the guide strand to form an active RISC [32, 
33].  The miRNA guide strand then binds to complementary mRNA and enables target mRNA 
cleavage by the RISC-associated endonuclease Argonaut2 (Ago2) (Figure 2.1A) [33]. As 
illustrated in Figure 2.1, anti-miRNA oligonucleotides (AMOs) molecules can be designed to 
inhibit either the mature miRNA in the active RISC complex or any of its precursors [34]. 
 Potential disadvantages in targeting miRNA precursors are that precursors are relatively 
transient species and not all miRNAs are equally susceptible to inhibition at the level of the pre- 
or pri-RNA [35]. Pri-miRNAs are especially difficult targets because they require inhibitor 
delivery to the nucleus. Consequently, most miRNA inhibitors (including the PNA anti-miRNA 
therapeutics used in this work) are designed to bind to and inhibit the activity of the mature miRNA 
guide strand once it is loaded into the RISC (Figure 2.1D) [36].  However, an alternative approach 
to inhibiting mature miRNA activity is to use “blockmir” technology.  Blockmirs are ~15mer 
oligonucleotides that are targeted to the mRNA instead of the miRNA; they function to target and 
competitively inhibit miRNA binding sites (Figure 2.1E) [37]. Because blockmirs target 
individual mRNAs, they may provide a means to reduce off-target effects and to achieve more 
predictable pharmacodynamics then anti-miRNA therapeutics that block all miRNA activities.  
This better specificity may aid clinical translation of anti-miRNA therapeutics, but it also abrogates 
the ability to develop therapeutics that simultaneously regulate multiple genes. Therefore, direct 
inhibition of mature miRNA remains the most high-impact and widely investigated strategy. 
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Figure 2.1. Sites of intervention for different anti-miRNA therapeutics along A) the miRNA 
biogenesis pathway. Anti-miRNA oligos (AMOs) are typically single stranded oligos that are 
introduced exogenously into the cell and can bind to B) pri-miRNA to inhibit Drosha activity or 
C) pre-miRNA to inhibit Dicer cleavage. D) AMOs are most commonly designed to bind to and 
inhibit mature miRNA. E) Blockmirs are oligonucleotides that block miRNA activity by 
specifically masking the 3’ UTR of target mRNA. [Adapted from Advanced Drug Delivery 
Reviews, 88, Kelsey R. Beavers, Christopher E. Nelson, Craig L. Duvall, “MiRNA inhibition in 
tissue engineering and regenerative medicine”, 123-127, 2014, with permission from Elsevier.] 
 
2.2 Anti-miRNA oligonucleotides 
Anti-miRNA oligonucleotides are the most prevalent class of miRNA inhibitors. There are several 
variants of AMOs utilized as anti-miRNA therapeutics, but they are all generally designed to be 
perfectly complementary to the full mature miRNA. Most AMOs bind to and sterically inhibit the 
binding of the RISC-loaded miRNA guide strand to target mRNAs (Figure 2.1D) [38]. Effective 
AMOs must have high specificity and strong binding affinity for target miRNA [31]. The first 
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AMO developed was a DNA oligo of complementary sequence and equal length to the target 
miRNA [39]. Later work revealed that the instability of unmodified DNA AMOs in serum severely 
limits effectiveness of miRNA inhibition in vivo [40]. Subsequent AMO designs have, therefore, 
focused on increasing AMO stability and endonuclease resistance, in addition to improving 
binding affinity to miRNA.  
Most AMOs are single stranded nucleic acids with modifications to the backbone 
chemistry incorporated to improve binding and/or impart nuclease resistance. The earliest tested 
AMO modifications included methylation of nucleoside ribose 2’ hydroxyl groups (Figure 2.2B).  
This “OMe” modification improves RNA binding affinity and contributes a modest improvement 
in nuclease resistance compared to unmodified sequences. However, OMe modified AMOs still 
suffer from relatively poor stability in serum [36]. Replacing the phosphodiester bonds in the AMO 
backbone with phosphorothiolate (PS) linkages is a more effective way of conferring nuclease 
resistance, but it also results in decreased AMO binding to target miRNA (Figure 2.2D) [41]. An 
additional modifier, N,N-diethyl-4-(4-nitronaphthalen-1-ylazo)-phenylamine, dubbed “ZEN” 
increases the binding affinity and nuclease resistance by enhancing steric blocking when 
positioned near the ends of OMe-modified RNA (Figure 2.2E) [38]. Antagomirs are another AMO 
derivative designed to improve the biostability and bioavailability of OMe oligos [42, 43]. 
Antagomirs possess a 3’ end conjugation to cholesterol which imparts nuclease resistance [43].  
As an added benefit, this hydrophobic cholesterol moiety enables antagomirs to better traverse the 
cell membrane and enter cells without the aid of a delivery vector.  However, clinical translation 
of antagomirs is limited as they require relatively high doses to achieve miRNA inhibition (up to 
80 mg kg-1 in a mouse model) [42], and have shown concerning off-target effects in vivo, as 
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evidenced by discrepancies in the cardiac phenotypes of animals with genetic depletions of miR-
21 and miR-133a and those treated with antagomirs against miR-21 and miR-133a [42, 44-46].  
The most effective, high-affinity AMO designs rely on highly-modified, synthetic 
oligonucleotide chemistries: locked nucleic acids (LNA), phosphorodiamidate morpholino 
oligonucleotides (PMOs), and PNA. LNA contain a methylene bridge between the 2’-O and 4’C 
of ribose to “lock” it into a configuration which is optimal for hybridization. LNA are also highly 
resistant to nuclease degradation (Figure 2.2C) [47].  Consequently, LNA-based AMOs show 
higher anti-miRNA activity at lower doses compared with the equivalent antagomir [48]. PMOs, 
another AMO derivative, substitute ribose with 6-membered morpholine rings, and 
phosphorodiamidates are used rather than phosphodiester bonds, making the overall molecule 
neutrally-charged (Figure 2.2F) [49]. These modifications sterically hinder nuclease binding and 
thus prevent enzymatic degradation of PMOs, but PMOs exhibit lower binding affinity for miRNA 
compared to LNA [49, 50]. In general, the AMO binding affinity listed from lowest to highest 
affinity follows the order: DNA<OMe oligos<PS-modified OMe oligos< ZEN-modified OMe 
oligos< PMO<LNA [38, 48, 49]. PNA, in comparison, have similar binding affinity and nuclease 
resistance to LNA [50]. This is the result of PNA’s chimeric structure, in which nucleobases are 
spaced along a peptide backbone (Figure 2.2G) [51]. PNA’s synthetic structure imparts both 
nuclease and protease resistance to PNA AMOs [15], while PNA’s charge neutrality allows it to 
bind with high affinity and specificity to miRNA targets [12]. PNA also has the unique advantage 
that it can be synthesized at large scales using standard peptide synthesis protocols [52]. 
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Figure 2.2. Common oligonucleotide modifications to improve anti-miRNA activity. A) The 2’ 
OH of ribose RNA can be methylated to create B) OMe-modified RNA, or a methylene bridge can 
be added between the ribose 2’-O and 4’-C to create C) locked nucleic acid (LNA). D) The 
phosphodiester bonds in the backbone can be replaced with phosphorothiolate (PS) bonds, or a E) 
ZEN modifier can be added between phosphate groups near oligo ends. Finally, neutrally-charged, 
synthetic F) phosphorodiamidate morpholino oligonucleotide (PMO) and G) peptide nucleic acid 
(PNA) chemistries can also be designed strongly inhibit miRNA. [Adapted from Advanced Drug 
Delivery Reviews, 88, Kelsey R. Beavers, Christopher E. Nelson, Craig L. Duvall, “MiRNA 
inhibition in tissue engineering and regenerative medicine”, 123-127, 2014, with permission from 
Elsevier.] 
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2.3 Anti-miRNA delivery considerations 
To be effective, anti-miRNA therapeutics need to be efficiently distributed in the target tissue site, 
internalized by the target cells, and trafficked to the cell cytosol where mature miRNA and the 
RISC machinery are located. Basic scientists often carry out in vitro mechanistic studies utilizing 
non-viral anti-miRNA delivery methods and reagents (e.g., cationic lipofection reagents) that do 
not meet these needs and are therefore not suitable for clinical use [53-56].  In contrast, other work 
has focused on developing agents that improve clinical anti-miRNA delivery and to expand the 
therapeutic index of anti-miRNA therapeutics. Examples of these agents include dendritic polymer 
nanoparticles [57], amphiphillic polymer micelles [58], gold nanoparticles [59, 60], lipid 
nanoparticles [48, 61, 62], and cell penetrating peptides (CPPs) [48, 63]. Conveniently, many of 
the advances in improving biodistribution and uptake for RNA-based drugs (such as shielding with 
PEG to improve circulation time, or conjugation to targeting antibodies) can be adapted for 
delivery of most AMOs [64].  
PNA by exception require additional delivery-vector design considerations due to their 
lack of charge. To enable electrostatic loading into carriers, or facilitate carrier-free cell uptake, 
PNA are often modified with charged amino acid residues such as lysine and arginine [65].  For 
example, modification of PNA with positively-charged lysine residues enabled effective in vivo 
miRNA inhibition at a 50 mg kg-1 PNA dose in mice [66]. Although the incorporation of positive 
charged moieties aids PNA intracellular delivery, it can also cause undesirable non-specific 
binding to DNA [67]. Minimizing these non-specific binding events is critical to preventing 
negative side effects of PNA therapeutics for eventual clinical application.  
One strategy for reducing off-target side effects is to modify PNA such that its uptake into 
cells is triggered by cues in the disease environment. For example, Cheng et. al. conjugated PNA 
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to a pH-responsive peptide which enables targeted PNA delivery to the acidic tumor 
microenvironment [68]. Additionally, the peptide utilizes an environmentally-activated non-
endocytic cell uptake / membrane transduction mechanism. This enabled miRNA inhibition at a 1 
mg kg-1 dose in a mouse model of lymphoma. Conjugation of PNA to an environmentally-
responsive peptide is effective at targeting tumor-associated miRNA; however, this strategy is 
limited to the inhibiting miRNAs in acidic microenvironments. Nanoparticles are a more versatile 
solution to the problem of PNA delivery. 
As an alternative to chemically modifying PNA, Babar et al. demonstrated that PNA 
encapsulation into poly(lactic-co-glycolic acid) (PLGA) nanoparticles coated with a cell-
penetrating peptide reduced the effective anti-miRNA PNA dose to 1.5 mg kg-1 in mice [69]. 
PLGA is a biocompatible and biodegradable material, but inefficient water in oil in water (W/O/W) 
emulsion is required for PLGA NP formation and PNA drug loading. Consequently, PLGA 
nanoparticles suffer from low PNA loading (0.35 wt% PNA). Low drug loading efficiency is 
common for PLGA nanoparticles and is considered the major hurdle limiting their clinical 
translation [70]. Although the PLGA study suggests that NPs can improve PNA anti-miRNA 
efficacy, a nanomaterial with higher drug-loading capacity is needed for clinical translation of 
PNA therapeutics. 
 
2.4 Porous silicon for drug delivery 
Porous silicon (PSi) is a promising biomaterial for PNA delivery [20]. Accidentally discovered at 
Bell Laboratories in 1956 [71], PSi is a versatile material that was spotlighted for biomedical 
applications in 1995 when Leigh Canham demonstrated that PSi is biodegradable and non-toxic 
[72]. In contrast to PLGA, PSi is an inorganic material with a large internal surface area (up to 800 
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m2 g-1) that can be exploited for PNA loading [73, 74].  PSi is typically fabricated using a top-
down approach, whereby the crystalline Si is porosified by electrochemical anodization.  
This process begins by immersing a clean, hydrogen-terminated silicon wafer in an organic 
solution (such as ethanol or acetonitrile) containing hydrofluoric acid (HF). The dissolution 
process that results in pore formation can be described by Equation 2.1. Under open circuit 
conditions, the surface of the silicon wafer is passivated by silicon hydride. When an anodic bias 
is applied to the wafer, an electronic hole (h+) migrates to the surface to catalyze replacement of 
superficial H atoms by highly electronegative fluoride ions (F-).  The Si-F bond created under this 
anodic bias is highly polar, opening up Si-Si bonds to nucleophilic attack by F- ions in the etchant 
solution. The progressive repetition of this process releases H2 gas and removes Si from the surface 
in the form of dissolved SiF6
2- species [75]. 
 
𝑆𝑖 + 4𝐻𝐹2
− + ℎ+ → 𝑆𝑖𝐹6
2− + 2𝐻𝐹 + 𝐻2 + 𝑒
−   (2.1) 
  
To form pores rather than electropolish the Si surface, the applied electrical current must 
be kept within a range such that anodization occurs preferentially at the tips of growing pores. 
During pore growth, electronic holes are depleted from the area adjacent to the silicon/electrolyte 
interface). The width of this depletion layer is dependent on the surface curvature.  Therefore, Si 
dissolution (pore growth) occurs only at the pore tip where the radius of curvature is largest and 
holes are available to participate in the dissolution reaction. As a consequence of this directional 
pore growth, the porosity, pore size, and pore depth can be tuned in situ to create complex 
structures such as the perforated multilayer in Figure 2.4. Perforated multilayer PSi can be used 
as a precursor material for the formation of PSNPs [76]. 
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Figure 2.3. Perforated PSi multi-layer for PSNP generation. A) Side-profile scanning electron 
micrograph of a 16-layer perforated PSi film used to generate PSNPs by ultrasonic fracture. B) 
Current profile used to generate the multilayer film shown in (A). [Adapted from Bioconjugate 
Chemistry, 25 (7), Kelsey R. Beavers et. al., “In Situ Synthesis of Peptide Nucleic Acids in Porous 
Silicon for Drug Delivery and Biosensing”, 1192-1197, 2014, with permission from the American 
Chemical Society.] 
 
PSi can be fabricated into particles with controlled porosity, shape, and size by tuning 
parameters such as wafer type and resistivity, the applied etch current time and density, and the 
electrolyte composition [19, 21, 25, 76]. Due to its prevalence as an electronic material, the 
technologies for fabricating and processing PSNPs are rapid, scalable, and relatively inexpensive. 
One commonly used, high-throughput means of generating PSNPs is through mechanical fracture 
of perforated multilayer PSi films (either by ball-milling or ultrasonication) [23, 76, 77]. After 
fabrication, PSNPs can be modified by a wide range of chemistries pioneered by the 
microelectronics industry.  
Chemical modifications such as oxidation, silanization, and hydrosilation have been used 
to tailor PSNPs for drug delivery applications [74]. In biological solutions, unoxidized PSNPs 
break down into orthosilicic acid: the non-toxic, natural bioavailable form of silicon that is easily 
metabolized by and excreted from the body [22, 78]. Thermal and chemical oxidation can be used 
to tune the half-life of PSNPs in biological solutions from the order of hours to weeks [79-81]. 
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Following oxidation, PSNP surfaces are decorated with hydroxyl groups that can be reacted with 
organic compounds to assist in grafting drugs or other biofunctional compounds to the particle 
surface. The variety of available PSi surface modifications allows PSNPs to efficiently load many 
different types of drugs. Proven PSNP payloads include large hydrophilic biomolecules like short 
interfering RNA (siRNA) [82], small hydrophobic molecules like the anti-inflammatory drug 
indomethacin [83], and neutrally charged molecules like PNA [24, 84]. 
As a consequence of their versatility, PSNPs have emerged as drug delivery vectors in 
broad range of biomedical applications. The Sailor group at the University of California, San 
Diego pioneered the use of PSNPs for in vivo tumor targeting and imaging [85]. Ferrari and co. 
later developed a multistage delivery system (MDS) consisting of PSi microparticles loaded with 
smaller nanoparticles for the treatment of cancer [21].  The shape and size PSi particles were 
engineered to improve MDS uptake in tumors where the subsequent release of nanoparticles 
delivers therapeutics to cancer cells [19]. In addition to tumor delivery, other groups have shown 
PSNPs improve drug delivery to numerous organs. These include the eye, liver, brain, and heart 
for the treatment diseases such as of proliferative vitreoretinopathy, hyperlipidemia, brain injury, 
and heart failure [24, 82, 86, 87]. Taken together these studies confirm that PSNPs are versatile, 
biocompatible NPs with high drug loading capacity and a demonstrated ability to overcome 
systemic delivery barriers in vivo. PSNPs are therefore poised to overcome the main challenges 
associated with PNA therapeutic delivery. 
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CHAPTER 3 
 
PSNP DESIGN AND DEVELOPMENT OF PNA LOADING STRATEGIES 
 
Text partially adapted from: 
Beavers KR, Mares JW, Swartz CM, Zhao Y, Weiss SM, Duvall CL. In Situ Synthesis of 
Peptide Nucleic Acids in Porous Silicon for Drug Delivery and Biosensing. Bioconjugate 
Chemistry. 2014; 25 (7): 1192-1197 
 
3.1 Introduction 
The advantageous properties of PSi (reviewed in section 2.4) have motivated a large body of 
research into PSi technologies for drug delivery. However, prior to the publication of this work in 
2014 [84], the only reported method of PNA attachment to PSi was nonspecific adsorption for 
nucleic acid biosensing [88]. There were no published studies for delivery of PNA-based 
therapeutics using PSNPs. Prior work seeking to improve PSi functionalization with biomolecules 
established methods for synthesizing peptides directly from PSi [89-91]. In addition, our group 
has shown that base-by-base synthesis of DNA directly within PSi films (referred to as in situ 
synthesis) significantly increases DNA loading relative to attachment of pre-synthesized oligos 
[92]. Building upon these results, this chapter describes the first use of PSi as a platform for the 
automated synthesis and label-free characterization of PNA. In situ PNA synthesis is compared 
against two other, non-electrostatic strategies for loading a PNA anti-miRNA therapeutic into 
oxidized PSi. It is shown that in situ PNA synthesis increases PNA loading relative to conjugation 
of the pre-synthesized molecule. The advantage of this approach is demonstrated for intracellular 
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delivery of  a well-characterized anti-miR122 PNA [93] which targets a liver-specific miRNA 
whose suppression has been linked to treatment of hyperlipidemia and hepatitis C viremia [94]. 
 
3.2 Materials and methods 
3.2.1 PSi and PSNP fabrication and characterization. PSi films are the precursor material for 
PSNPs. Additionally, PSi films are advantageous substrates for solid-state PNA synthesis 
(discussed in section 3.2.2) and for evaluation of PNA loading efficiency (discussed in section 
3.2.6). This is because reflectometry can non-destructively quantify changes in pore content by 
measuring changes in PSi film optical thickness. Optical thickness, defined below in Equation 
3.1, is the product of the effective refractive index of PSi (neff) and the thickness of the PSi film 
(L). Effective medium theory states that neff   is a function of both the refractive index of the silicon 
matrix and that of the pore filling material [95]. Consequently, changes in optical thickness are 
directly correlated with changes in PNA loading. 
 
𝑂𝑝𝑡𝑖𝑐𝑎𝑙 𝑇ℎ𝑖𝑐𝑘𝑛𝑒𝑠𝑠 = 2𝑛𝑒𝑓𝑓𝐿    (Equation 3.1) 
 
PSi films used for optical evaluation of PNA loading efficiency were etched from p-type 
Si (0.01Ω-cm) using 15% hydrofluoric acid in ethanol to form 10 µm thick single layers (70% 
porosity, 30 nm average pore diameter). Multilayer films used for PSNP generation were 
fabricated by multiple repetitions of two anodization steps: 50 mA/cm2 for 8 s to yield “particle” 
layers with 70% porosity, and 60 mA/cm2 for 2 s to form mechanically fragile “lift-off” layers 
(Figure 2.3). All porous silicon films were thermally oxidized at 800°C for 30 min in ambient air.  
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To generate PSNPs, multilayer films were ultrasonicated in isopropanol (IPA) for 2 h after 
completion of in situ PNA synthesis. Deionized water was used to reduce the concentration of IPA 
in the sonicated particle suspension to 65%. PSNPs were then filtered through a 2.6 µm syringe 
filter and immediately isolated using a 10 kDa molecular weight cutoff centrifugal filter to separate 
free PNA from PNA-conjugated PSNPs. Free PNA was collected from the filtrate, and PNA-
functionalized particles (PNA-PSNPs) were collected from the concentrate. Aliquots of both the 
free PNA and PNA-PSNPs solutions were taken for analysis by UV-Vis spectroscopy and 
nanoparticle tracking analysis (NTA) [96]. To quantify the amount of PNA conjugated to PSNPs, 
a known concentration of PNA-PSNPs was dissolved in 5x PBS overnight, and PNA concentration 
was determined by measuring PNA absorbance at 260 nm.   
 
3.2.2 In situ PNA synthesis. Oxidized PSi films were functionalized with 3-
aminopropyltriethoxysilane (APTES) by drop-casting a solution of 1% APTES in anhydrous 
toluene onto the porous surface and incubating the sample at room temperature for 10 min. 
Following APTES attachment, films were rinsed 3x with ethanol to remove excess silane. The 
silanized films were thermally annealed at 150ºC for 15 min to promote stable APTES monolayer 
formation, and the films were then soaked at room temperature in deionized water for 3 h to remove 
any unwanted silane multilayers.  
In situ synthesis of anti-miR122 PNA (NH2-ACA AAC ACC ATT GTC ACA CTC CA-
COOH) was conducted directly on APTES-functionalized PSi within a custom reaction vessel 
(Figure 3.1). A schematic of the synthesis process is presented in Figure 3.2. After synthesis, 
Bhoc protecting groups were removed from nucleobases by 10 min incubation with 5% (v/v) 
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anisole in trifluoroacetic acid (TFA), followed by 5 min washing with dichloromethane (DCM), 
2x, rinsing with methanol, 3x, drying under nitrogen gas, and storage in a vacuum desiccator.  
To investigate whether pore widening improves monomer coupling efficiency for longer 
oligos, changes in optical thickness were monitored during synthesis of anti-miR122 PNA from a 
KOH-exposed PSi film (Figure 3.6).  Following electrochemical etching, PSi films were exposed 
to a 9 mM pore-widening solution of KOH in ethanol at room temperature for 20 min. Pore size 
distributions were quantified from SEM micrographs using ImageJ analysis software.  
 
 
Figure 3.1. Custom reaction vessel for the in situ synthesis of PNA on PSi films. 
Reaction Vessel 
PSi Sample 
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Figure 3.2. In situ synthesis of PNA from a PSi film solid support (shaded box). Each base addition 
requires (Ia) Fmoc deprotection of growing PNA chains on the PSi surface, 2x, (Ib) activation of 
PNA monomer C-termini and (II) coupling of preactivated monomers to growing PNA oligos, 3x, 
followed by either (III) automated repetition of the cycle to further elongate PNA oligos, or (IV) 
final deprotection of N-termini and exit from the cycle. [Adapted from Bioconjugate Chemistry, 
25 (7), Kelsey R. Beavers et. al., “In Situ Synthesis of Peptide Nucleic Acids in Porous Silicon for 
Drug Delivery and Biosensing”, 1192-1197, 2014, with permission from the American Chemical 
Society.] 
 
3.2.3 Pre-synthesized PNA conjugation. Pre-synthesized cys-PNA was conjugated to APTES-
functionalized PSi via an amine-to-sulfhydryl heterobifunctional crosslinker, N-succinimidyl 3-
(2-pyridyldithio) propionate (SPDP) (Figure 3.3). SPDP was first reacted with the freshly-
silanized surface in ethanol at room temperature for 1 h using a 20x molar excess of SPDP. The 
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number of successfully attached SPDP groups was quantified with a control sample by reducing 
conjugated SPDP with TCEP and measuring absorbance of released pyridine-2-thione at 343 nm.  
Prior to attachment, pre-synthesized cys-PNA dissolved in deionized water was reduced 
on immobilized TCEP resin. Immediately afterwards, the SPDP-functionalized PSi film was 
incubated with the reduced cys-PNA at a PNA:SPDP molar ratio of 4:1. The reaction was allowed 
to proceed at room temperature on a shaker for 2 h, after which the reaction supernatant was 
removed and retained for subsequent characterization. The PNA-conjugated film was rinsed 3x 
with water, 2x with ethanol and 2x with methanol, then dried with nitrogen gas and stored in a 
desiccator under vacuum. Reaction efficiency was quantified by comparing moles of pyrdine-2-
thione released from PNA attachment to moles of SPDP conjugated to the surface.  
 
 
 
Figure 3.3.  Direct conjugation of pre-synthesized PNA to a PSi film (shaded box). [Adapted from 
Bioconjugate Chemistry, 25 (7), Kelsey R. Beavers et. al., “In Situ Synthesis of Peptide Nucleic 
Acids in Porous Silicon for Drug Delivery and Biosensing”, 1192-1197, 2014, with permission 
from the American Chemical Society.] 
 
 
3.2.4 Physical PNA adsorption. Physical adsorption of PNA (Figure 3.4) was accomplished using 
by incubating oxidized PSi films with PNA in water at an equivalent concentration to that used to 
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conjugate pre-synthesized PNA to PSi (1 µmole PNA/2.6 mg PSi) for 2 hours at room temperature. 
Following incubation, films were washed 3x with water, 2x with ethanol and 2x with methanol.  
In these films, PNA are either adsorbed to the PSi internal surface, or absorbed within the open 
pore volume. 
 
Figure 3.4.  Physical adsorption of pre-synthesized PNA to an oxidized PSi film (shaded box). 
[Adapted from Bioconjugate Chemistry, 25 (7), Kelsey R. Beavers et. al., “In Situ Synthesis of 
Peptide Nucleic Acids in Porous Silicon for Drug Delivery and Biosensing”, 1192-1197, 2014, 
with permission from the American Chemical Society.] 
 
3.2.5 Mass spectrometry. Matrix assisted laser desorption-ionization mass spectrometry (MALDI-
MS) was utilized to confirm the expected mass of the synthesized PNA [97]. MALDI spectra were 
acquired using a Voyager DE-STR mass spectrometer in linear, positive mode with an external 
Nd:YAG laser ionization source (frequency tripled, 355 nm).  The matrix employed for the 
MALDI measurement consisted of either 2.5 mg of 3,5-dimethoxy-4-hydroxycinnamic acid 
(sinapinic acid) or 1 mg of α-cyano-4-hydroxycinnamic acid (CHCA), dissolved into 100 µL of a 
7:3 v/v solution of acetonitrile:water, with 2 µL of 10% TFA.  To liberate PNA from PSi, an area 
of PNA-loaded porous silicon film (approximately 6 mm2) was scraped into 40 µL of deionized 
water, sonicated for several minutes and allowed to dissolve for approximately 1 h.  This 
suspension was then added in equal volume to the matrix solution and agitated.  The matrix was 
drop-cast onto a conventional stainless steel MALDI plate and dried prior to measurement. 
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3.2.6 In vitro PNA loading and release. PNA loading studies were performed by monitoring the 
change in optical thickness of dry PSi films before and after PNA loading. Optical thickness was 
quantified as the peak in the Fourier transform of the PSi reflectivity spectrum, taken with a 
spectrophotometer (Ocean Optics, Dunedin, FL, USA). Release studies were performed by 
incubating PNA-loaded PSi films in 1x PBS at 37ºC. Releasate was collected at pre-determined 
times and analyzed for PNA concentration by monitoring the absorbance of the nucleic acid at 260 
nm. Collected releasate was replaced with fresh PBS to maintain infinite sink conditions over the 
course of the study. 
 
3.2.7 Cell culture and biological assays. All Huh7 human hepatic carcinoma cells were 
maintained in Dubelco’s modified eagle medium (DMEM) containing 10% fetal bovine serum 
(FBS), 2% penicillin-streptomycin antibiotics, and 2µg mL-1 ciprofloxacin at 37ºC/5% CO2. To 
enable visualization of intracellular PNA delivery, N-termini of free and PSi-bound PNA were 
labeled with NHS-Alexa-488 at a molar ratio of 1:2 (Alexa:PNA). Excess NHS-Alexa and reaction 
byproducts were removed by sequential centrifugal filtration (3 kDa cutoff centrifugal filters) and 
resuspension in deionized water, 4x. Alexa-labeled free PNA and PNA-PSNPs were then 
lyophilized for storage until used.  
Cells were seeded onto 8-well chamber slides (Thermo Fisher Scientific Inc., Waltham, 
MA) at a density of 12,500 cells/well and incubated at 37ºC for 8 h. Cells were then treated for 
either 1 or 24 h with free PNA or PNA-PSNPs at a 2 µM dose of PNA (~3.7 µg mL-1 PSNPs for 
PNA-PSNP treatments). Subsequently, the cells were washed with PBS and stained for 5 min with 
Hoechst nuclear dye prior to imaging with confocal microscopy (Zeiss LSM 710Meta, 
Oberkochen, Germany).  
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PSNP cytotoxicity was determined using a lactate dehydrogenase CytoTox-ONE™ 
homogenous membrane activity assay (Promega Corporation, Madison, WI). Huh7-psiCHECK-
miR122[98] cells were seeded at 6,000 cells per well in black, clear-bottom, 96-well plates (BD 
Falcon, San Jose, CA) and incubated at 37ºC for 8 h. Cells were then treated with free PNA, empty 
PSNPs, or PNA-PSNPs at a 2 µM dose of PNA (~3.7 µg mL-1 PSNPs for PSNP and PNA-PSNP 
treatments) in DMEM containing 1% FBS for 24 h at 37ºC/5% CO2. Note that all PSNPs in this 
study were fabricated from pore-widened PSi. After 24 h, the cells were washed with PBS and the 
media was replaced with DMEM containing 10% FBS, 2% penicillin-streptomycin, and 2 µg mL-
1 ciprofloxacin. Cells treated with a miR-122 antagomir (AMO) (2′-OMe PS modified 
oligonucleotide 5′ ACAAACACCAUUGUCACACUCCA 3′; IDT DNA)[40, 98] were transfected 
using Fugene 6 (3 µL reagent: 1 µg AMO) (Promega) in Opti-Mem media. Cells treated with AMO 
were incubated at 37 °C for 4 h followed by the replacement of transfection media with standard 
DMEM growth media. The cell viability was determined after 44 h after treatment according to 
the manufacturer’s proliferation assay protocol. 
Luciferase anti-miR122 activity was evaluated in Huh7 cells modified to increase the 
expression of Renilla Luciferase in response to miR-122 inhibition. These Huh7-psiCHECK-
miR122[98] cells were seeded at 6,000 cells per well in black, clear-bottom, 96-well plates (BD 
Falcon, San Jose, CA) and incubated at 37ºC for 8 h. Cells were then treated with free PNA, empty 
PSNPs, or PNA-PSNPs at a 2 µM dose of PNA (~3.7 µg mL-1 PSNPs for PSNP and PNA-PSNP 
treatments) in DMEM containing 1% FBS for 24 h at 37ºC/5% CO2. Note that the PSNPs and 
PNA-PSNPs in this study were fabricated from pore-widened PSi. After 24 h, the cells were 
washed with PBS and the media was replaced with DMEM containing 10% FBS, 2% penicillin-
streptomycin, and 2 µg mL-1 ciprofloxacin. As a positive control, an optimized AMO (2′-OMe PS 
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modified oligonucleotide 5′ ACAAACACCAUUGUCACACUCCA 3′; IDT DNA)[40, 98] was 
transfected using Fugene 6 (3µL reagent: 1 µg AMO) (Promega) in Opti-Mem media. Cells treated 
with AMO were incubated at 37 °C for 4 h followed by the replacement of transfection media with 
standard growth media. Luciferase activity was measured based on bioluminescence using an in 
vivo imaging system (IVIS; Perkin Elmer, Waltham, MA) after addition of luciferase substrate. 
 
3.3 Results and discussion 
 In situ PNA synthesis was characterized by reflectometry and matrix assisted laser desorption-
ionization mass spectrometry (MALDI-MS) (Figure 3.5). Increases in optical thickness are 
directly proportional to the amount of monomer coupled to growing PNA oligos within the PSi 
film [99]. Addition of the first 9 bases resulted in a stepwise increase in optical thickness, while 
the change in optical thickness was increasingly non-linear for the addition of nucleobases 10-23 
(Figure 3.5A).  
To verify synthesis of the desired PNA sequence, in situ synthesized PNA was analyzed 
by mass spectrometry at two critical points during synthesis: after completion of the 9-mer miRNA 
seed-targeting sequence and after the full 23-mer anti-miRNA (Figure 3.5B). The seed-targeting 
sequence of therapeutic PNA is the most important miRNA-binding motif [93], whereas the full 
23-mer sequence improves PNA target specificity and anti-miRNA activity [93]. MALDI spectra 
of the 9-mer seed-targeting sequence contained a single peak corresponding to the expected 
molecular weight of the APTES-conjugated PNA, 2485 Da, and two additional, closely-spaced 
peaks corresponding to Na+ and K+ adducts were resolved at 2507 Da and 2523 Da, respectively.   
MALDI spectra of the full 23-mer PNA revealed an intense peak at the expected m/z for the full 
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PNA oligo, 6243 Da, as well as a series of less intense peaks grouped at molecular weights 
corresponding to PNA sequences that were truncated during synthesis.  
It is postulated that steric crowding of the growing PNA oligos within nano-sized pores 
causes the partial truncation seen during in situ synthesis [100].  The molecular length of APTES 
is approximately 8 Å [101], and each PNA base extends a growing oligo by approximately 3.5 Å 
[102]. Thus, the full, 23-mer PNA is estimated to be 8.9 nm in length. Electrochemical 
porosification of Si produces a Gaussian-like  distribution of pore sizes, so while the average pore 
diameter of PSi films in this study is 30 nm, it is estimated that approximately 40% of the pores 
are between 10 and 25 nm in diameter [103]. To investigate whether the yield of longer oligos can 
be improved by increasing the minimum pore size, anti-miR122 PNA was synthesized from a PSi 
film that was first exposed to a pore-widening solution of potassium hydroxide (KOH) in ethanol 
at room temperature for 20 min (Figure 3.6). Pore widening increased the average pore diameter 
by 5 nm and decreased the number of pores with diameter less than 25 nm by ~20%, resulting in 
increased shifts in optical thickness during in situ synthesis (Figure 3.6). These data suggest that 
longer oligos can be more efficiently synthesized within a porous silicon matrix by increasing the 
average pore size. Although it was outside the scope of our testing, it may also be beneficial to 
utilize a fabrication method that yields more homogenous pores. Since pore widening improved 
synthesis of the 23-mer anti-miR122, it was implemented for in vitro functional studies, i.e. 
cytotoxicity and bioactivity assays (all other studies were done with non-pore-widened substrates). 
Overall, these results, combined with subsequent experimental readouts, are a promising 
demonstration of successful synthesis of functional 23-mer PNA from PSi, with highly efficient 
growth of the vital anti-miR122 PNA seed sequence.   
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Figure 3.5. Characterization of in situ PNA synthesis and comparison of PNA loading methods. 
A) Non-destructive optical characterization of in situ synthesis of 23-mer anti-miR122 PNA using 
reflectometry and Fourier transform analysis to determine the optical thickness of the loaded PSi 
film. B) MALDI-TOF mass spectrometry of in situ synthesized 9-mer miRNA seed targeting 
sequence (top) and the full 23-mer PNA (bottom). C) Comparison of the PNA loading capacity 
achieved using in situ synthesis, physical adsorption, and direct conjugation of a 23-mer PNA to 
PSi. Loading was calculated based on increase in optical thickness due to the addition of PNA to 
the PSi surface. (* P<0.0001) [Adapted from Bioconjugate Chemistry, 25 (7), Kelsey R. Beavers 
et. al., “In Situ Synthesis of Peptide Nucleic Acids in Porous Silicon for Drug Delivery and 
Biosensing”, 1192-1197, 2014, with permission from the American Chemical Society.] 
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Figure 3.6. Pore widening improves in situ PNA synthesis. A) Top-view of PSi films before and 
after KOH pore-widening (SEM; scale bars=100nm). B) Characterization of optical thickness 
profile during PNA synthesis to illustrate changes in monomer coupling efficiency and yield of 
longer oligos following pore widening. Results are normalized to the optical thickness of each 
film’s corresponding optical thickness following APTES functionalization. [Adapted from 
Bioconjugate Chemistry, 25 (7), Kelsey R. Beavers et. al., “In Situ Synthesis of Peptide Nucleic 
Acids in Porous Silicon for Drug Delivery and Biosensing”, 1192-1197, 2014, with permission 
from the American Chemical Society.] 
 
Optical thickness measurements were also used to determine the amount of anti-miR122 
PNA loaded within PSi through in situ synthesis compared to standard methods of physical 
adsorption and conjugation of pre-synthesized PNA (Figure 3.5C). Consistent with our previous 
studies of DNA conjugation to PSi [92],  PNA loading from in situ synthesis was 8-fold greater 
than the amount of PNA loading achieved from conjugation to a PSi surface. This corresponds to 
a yield of 8.6 × 10-4 moles PNA per g PSi, or 5.3 g PNA per g PSi for anti-miR122 synthesized in 
situ in non-pore widened PSi, quantified by measuring the absorbance at 260 nm of PNA released 
after dissolution of the PSi matrix. It is postulated that during PNA loading by direct conjugation, 
PNA preferentially attaches nearer to the pore openings at the film surface, thereby restricting 
access of PNA deeper into the pores. Interestingly, there was no significant difference in the 
loading efficiency of in situ synthesis and physical adsorption within the pores. It is hypothesized 
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that, in the case of nonspecific PNA loading by adsorption, lack of PNA covalent binding allows 
PNA to freely diffuse further into the pores and achieve a level of loading similar to in situ 
synthesis. Although nonspecific adsorption yielded a similar level of loading, we later demonstrate 
in Figure 3.7 that the covalent attachment achieved from in situ synthesis provides more sustained 
release in the context of therapeutic PNA delivery. 
 To evaluate PNA therapeutic delivery potential, the in vitro PNA temporal release profile 
of in situ synthesized PNA from PSi films was compared to that of physically adsorbed PNA 
(Figure 3.7A). Release of PNA synthesized in situ was significantly (p<0.005) less than adsorbed 
PNA at every time point within the first 24 h. Overall, the PNA synthesized in situ showed reduced 
initial burst and more sustained release profiles. It is anticipated that hydrolytic degradation of the 
PSi matrix is the primary mechanism of PNA release because in situ synthesized PNA are 
covalently attached to pore walls. In situ synthesis therefore provides more controlled PNA 
delivery when compared to physical adsorption [91, 104]. Mass spectra in Figure 3.5B provide 
support for a surface-degradation PNA release mechanism because the molecular weight of PNA 
released from in situ films corresponds to APTES-conjugated PNA.  
PNA anti-miRNA activity is dependent upon delivery into the cytoplasm where active 
micro-RNA is located [93]. To demonstrate the application of in situ PNA synthesis for drug 
delivery, anti-miR122-loaded multilayer PSi films were ultrasonically fractured to produce PNA-
functionalized PSNPs. The resultant PSNP mean size (236 nm) and size distribution were 
determined by Nanoparticle Tracking Analysis (NTA) and confirmed by scanning electron 
microscopy (SEM) (Figure 3.7B). 
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Figure 3.7. In vitro characterization of PNA-PSNP morphology and bioactivity A) Cumulative 
release of physically-adsorbed PNA and in situ synthesized PNA in PBS at 37°C. Release of in 
situ synthesized PNA was significantly lower (p<0.005) for time points within the boxed region. 
B) PNA-PSNP size distribution characterized by NTA. Inset: Representative SEM image 
demonstrating PSNP size and morphology (scale bar=400nm). C-F) Confocal micrographs of 
Huh7 cells incubated for either 1 or 24 h with (C and D) free PNA, or (E and F) PNA-PSNPs at 
a 2 µM dose of anti-miR122 PNA (3.7 µg mL-1 PSNPs for PNA-PSNP treatments). Labels: 
Hoechst nuclear dye (blue), Alexa-488 labeled PNA (green). G) PSNPs had no significant effect 
on Huh7 cell viability relative to untreated negative control samples, in contrast to a 2’OMe-
modified AMO delivered with Fugene 6 (p<0.05). H) Anti-miR122 activity indicated by luciferase 
activity in Huh7-psiCHECK-miR122 cells 44 h after treatment with free PNA, empty PSNPs, or 
PNA-PSNPs (2 µM dose of anti-miR122 PNA, 3.7 µg mL-1 PSNPs). Results are normalized to 
cell number and expressed relative to luciferase activity in Huh7-psiCHECK-miR122 control 
cells without treatment. Dashed green line indicates anti-miR122 activity 44 h after treatment with 
2 µM of an optimized anti-miR122 AMO delivered via the Fugene 6 commercial transfection 
reagent [40]. [Adapted from Bioconjugate Chemistry, 25 (7), Kelsey R. Beavers et. al., “In Situ 
Synthesis of Peptide Nucleic Acids in Porous Silicon for Drug Delivery and Biosensing”, 1192-
1197, 2014, with permission from the American Chemical Society.] 
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Huh7 human hepatic carcinoma cells were selected for evaluation of PNA-PSNP cellular 
uptake, cytotoxicity, and anti-miRNA activities because they express elevated levels of miR122. 
Huh7 cells therefore provide a good platform for testing anti-miR122 therapies [93, 98]. 
Intracellular delivery of a 2 µM dose of fluorescently-labeled free or in situ synthesized PSNP 
anti-miR122 PNA was evaluated by confocal microscopy (Figure 3.7 C-F). At each treatment 
time, cells treated with PNA-PSNPs showed greater intracellular delivery of PNA relative to those 
treated with free PNA.  Additionally, a lactate dehydrogenase enzymatic assay was used to 
compare the cytotoxicity of PNA-PNSPs to that of a 2’OMe-modified anti-miRNA 
oligonucleotide (AMO) delivered by the commercial transfection reagent, Fugene 6 (Promega) 
(Figure 3.7G). Consistent with previous studies on the cytotoxicity of thermally-oxidized PSi 
nanoparticles [105], no reduction in cell viability was observed for the PSNP concentration 
investigated in this study (2 µM PNA, 3.7 µg mL-1), whereas AMO treatment led to a 25% decrease 
in cell viability at an equivalent dose.  
 Finally, Huh7 cells stably transfected with a psiCHECK-miR122 Renilla luciferase 
reporter for endogenous miR122 activity [98] were used to determine the anti-miRNA activity of 
PNA in situ synthesized on pore-widened PSi prior to ultrasonic particle formation (Figure 3.7H). 
In this reporter cell line, luciferase is translated upon inhibition of miR122.  PSNP delivery of a 2 
µM dose of in situ synthesized anti-miR122 PNA triggered a significant, 44% increase in luciferase 
activity at 44 hours after treatment, while treatment with an equivalent dose of free PNA or empty 
PSNPs had no significant effect relative to untreated controls. These results provide evidence that 
PSNPs improve the intracellular delivery and bioactivity of therapeutic PNA without the need for 
fusion with cell-penetrating peptides or use of cytotoxic transfection reagents, such as that used to 
deliver the AMO control in this study.  
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3.4 Conclusion 
A new method for automated PNA synthesis from PSi has been developed and applied for anti-
miRNA drug delivery. The optical properties of nano-structured PSi were exploited to non-
destructively monitor synthesis progression with single-base resolution. In situ synthesis addresses 
the need for efficient, covalent conjugation of PNA to PSi—demonstrated by 8-fold greater PNA 
loading when compared to covalent attachment of pre-synthesized PNA to the surface via a cross-
linker.  In situ synthesis is equally efficient as physical adsorption at loading PNA into PSi, and 
the covalent means of attachment enabled greater control of PNA release. However, physical 
adsorption is a promising alternative method for drug loading provided that the carrier incorporates 
a secondary means to minimize PNA burst release (such as the polymer coating introduced in 
Chapter 4). Anti-miR122 PNA-loaded PSi nanoparticles were biocompatible and increased the 
intracellular delivery and bioactivity of therapeutic PNA. Taken together, these studies 
demonstrate the utility of PSNPs for developing improved systems for controlled intracellular 
delivery of PNA therapeutics. 
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CHAPTER 4 
 
DEVELOPMENT OF A PSNP NANOCOMPOSITE TO IMPROVE PNA 
THERAPEUTIC ACTIVITY IN VIVO 
 
Text adapted from: 
Beavers KR, Werfel TA, Shen T, Kavanaugh TE, Kilchrist KV, Mates JW, Fain JS, Wiese CB, 
Vickers KC, Weiss SM, Duvall CL. Porous Silicon and Polymer Nanocomposites for Delivery of 
Peptide Nucleic Acids as anti-microRNA Therapies. Advanced Materials. 2016. 
 
4.1 Introduction 
As discussed in Chapter 2, inhibition of disease-associated miRNA is a potentially potent 
therapeutic strategy because a single miRNA can control the expression of hundreds of different 
genes [106]. PNA have been successfully delivered in vitro using approaches such as fusion with 
cell penetrating peptides or lipophilic moieties [107], but the clinical translation of PNA anti-
miRNA therapeutics is limited by physiologic delivery barriers. These barriers include poor 
cellular uptake, lack of endosomal escape, and rapid clearance following intravenous delivery (<5 
min blood circulation half-life) [16]. While the neutrally-charged PNA backbone can provide a 
functional advantage, it obviates the use of conventional nucleic acid delivery strategies that rely 
on charge, such as formulation with cationic polymers and lipids to form nanomedicines. To 
overcome these delivery barriers and formulation challenges, we have developed polymer/porous 
silicon nanocomposites with high cargo loading capacity independent of electrostatics, stability in 
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the blood based on surface PEGylation, and endosomal escape functionality to facilitate PNA 
delivery to the cytoplasm where miRNA targets are located [108]. 
Chapter 3 demonstrated that packaging PNA into “naked” porous silicon nanoparticles 
(PSNPs) improves the cellular uptake and therapeutic activity of PNA in vitro [84]. However, after 
internalization, porous silicon cannot efficiently trigger release of PNA from endo-lysosomal 
vesicles into the cytoplasm [109], and we have observed that PSNPs are not colloidally stable at 
high concentrations in saline solutions amenable to intravenous administration. One PSNP 
modification strategy to enable endosomal escape, developed by the Santos group, is to covalently 
attach a zwitterionic copolymer of polyethyleneimine (PEI) and poly(methyl vinyl ether-co-maleic 
acid) (PMVE-MA) to the porous silicon surface [109]. PEI, which is debated to mediate endosome 
escape via a proton sponge mechanism [110, 111], was shown to improve endosomal escape and 
therapeutic activity of the small molecule drug methotrexate in these studies (though not larger 
biologics).  The PMVE-MA-based particles have a highly negative zeta potential (-31.7 ±1.7mV) 
which is associated with poor in vivo pharmacokinetics relative to surface charge neutral 
nanoparticles [112]. Furthermore, PMVE-MA activates the innate immune system through both 
toll like receptor and complement activation pathways and thus is not an ideal material for systemic 
therapeutic applications [113]. Nanoprecipitation-based coating of hydrophobic porous silicon 
nanoparticles with amphiphilic block-copolymers containing poly(histidine) has also been 
explored for pH-triggered release of small molecules. However, this approach has not been utilized 
to deliver intracellular-acting biologics and its potential endosomal-disrupting function has not 
been explored [114]. 
Our group recently developed an endosomolytic polymer poly[(ethylene glycol) – block – 
(2-(dimethylamino)ethyl methacrylate – co – butyl methacrylate)] (PEGDB), and tuned it to have 
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optimal endosomal escape properties for systemic delivery of negatively-charged nucleic acids 
[28]. PEGDB consists of a hydrophilic PEG block and a second block comprising 50:50 mol% of 
cationic and pH-responsive 2-(dimethylamino)ethyl methacrylate (DMAEMA; D) and 
hydrophobic butyl methacrylate (BMA; B). The resulting polymer is finely tuned to disrupt 
membranes in acidic environments representative of early (pH 6.8) and late endosomes (pH 6.2) 
but not at physiologic pH (pH 7.4) [28]. Neutrally charged PNA cannot be electrostatically loaded 
into PEGDB polyplexes. Here, we explored oxidized, PNA-loaded PSNPs with a highly negative 
surface charge as “scaffolds” for PEGDB electrostatic surface coating. We demonstrate that this 
approach yields surface charge neutral composite NPs with enhanced stability, improved 
pharmacokinetics, and increased cytosolic delivery and bioactivity of PNA relative to PSNPs 
without a polymeric coating. 
 
4.2 Materials and methods 
4.2.1 PSNP fabrication. PSi films were etched from p-type Si (0.01Ω-cm) using 15% hydrofluoric 
acid in ethanol. Multilayer films used for PSNP generation were fabricated by multiple repetitions 
of two anodization steps: 60 mA cm-2 for 8 s to yield “particle” layers with 75% porosity, and 100 
mA cm-2 for 2 s to form mechanically fragile “lift-off” layers. Afterwards, PSi films were fractured 
into particles by ultrasonication in H2O2 for 2 h. To further oxidize the particle surfaces, 
ultrasonicated PSi in H2O2 was transferred to a hotplate and heated while stirring at 115°C for 4 
hours.  The particles were then transferred to ultracentrifuge tubes and washed 3x by pelleting at 
14.1 x g for 15 min and replacing the supernatant with fresh ethanol.  Following the final wash 
step, PSNPs were isolated from larger debris by centrifuging at 300 x g and collecting the smaller 
nanoparticles in the supernatant. 
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4.2.2 PNA synthesis and loading. Non-specific adsorption, rather than in situ PNA synthesis, was 
selected as the method for PNA loading in this chapter so that the negatively-charged PSNP surface 
would be accessible for PEGDB coating. Cysteine-modified anti-miR122 PNA (NH2-ACA AAC 
ACC ATT GTC ACA CTC CA-cys-COOH) used in this chapter was synthesized from Rink 
Amide LL resin (EMD Millipore) using fluorenylmethyloxycarbonyl chloride (Fmoc) solid phase 
chemistry within a PS3 automated peptide synthesizer (Protein Technologies). Note that all PNA 
used in Chapter 4 was modified by addition of a single cysteine at the C-terminus of the PNA. This 
was done to promote crosslinking of PNA following loading into PSNPs and reduce PNA diffusion 
from pores. PNA was purified by reverse-phase high-pressure liquid chromatography using a 
Waters 1525 series HPLC equipped with a Phenomenex Luna C18 (10 x 250 mm, 5μm) column 
(linear gradient from 99% H2O 0.01% formic acid to 40% ACN 0.01% FA in 18 minutes with a 
flow rate of 3 mL min-1). PNA was confirmed to be >99% pure by liquid chromatography-mass 
spectrometry (LC-MS). 
Fluorescent PNA used in cell uptake and co-localization studies were labeled by coupling 
the PNA N-termini to Oregon Green 488 carboxylic acid, succinimidyl ester. Similarly, fluorescent 
PNA used in circulation half-life and biodistribution studies were labeled by coupling N-termini 
to Cy5 N-hydroxysuccinimidyl ester. In both cases, PNA and fluorophores were reacted for 1 hour 
in PBS containing (tris(2-carboxyethyl)phosphine) at pH 7.5. Fluorescent PNA was purified from 
unreacted products using a PD Miditrap G-10 desalting column (GE Healthcare Life Sciences). 
PNA was loaded into PSNPs by non-covalent physical adsorption. Composite PSNPs were 
impregnated with PNA prior to polymer coating. PNA dissolved in deionized H2O was added to a 
solution of oxidized PSNPs in H2O at a 1:2 PNA:PSNP weight ratio. The PNA/PSNP solution was 
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briefly ultrasonicated and then mixed on a shaker at room temperature for 3 hours. Finally, PNA-
loaded PSNPs were frozen at -80°C and lyophilized overnight. Excess PNA was purified from 
drug loaded PSNPs by suspending lyophilized particles in H2O, centrifuging particles at 15k x g 
for 15 min, then removing the supernatant. 
PNA loading was quantified by first dissolving/degrading the PSi substrate in PBS with 10 
mM KOH for 48 hours at 37°C. Samples were then spun at 15,000 x g for 10 min, and 150 µL of 
supernatant was removed and analyzed for PNA content by liquid chromatography mass 
spectrometry (LCMS). The gradient described in Table 4.1 was used to separate any polymer or 
silicon from the PNA, which was detected in elutant at 6.5 min after injection. PNA concentration 
was calculated by integration of the peak at 6.5 min in the total ion count (TIC) chromatograph, 
and comparing against a standard curve of free PNA injected under the same conditions. 
 
Table 4.1. LCMS Gradient for PNA purification. Solvent A=H2O+0.05% Formic Acid, and 
solvent B=CAN. 
 
Time (min) Flow (ml min-1) %A %B 
0 0.3 99 1 
1 0.3 99 1 
5 0.3 95 5 
10 0.3 0 100 
11 0.3 0 100 
15 0.3 99 1 
 
 
4.2.3 PEGDB polymer synthesis. The reversible addition-fragmentation chain transfer (RAFT) 
chain transfer agent for polymer synthesis, ECT, was synthesized as previously described, and the 
R-group of the chain transfer agent was subsequently conjugated to PEG. Briefly, 
dicyclohexylcarbodimide (4 mmol, 0.82 g) was added to the stirring solution of monomethoxy-
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poly(ethylene glycol) (Mn = 5000, 2 mmol, 10 g), ECT (4 mmol, 1.045 g), and 4-
dimethylaminopyridine (DMAP, 10 mg) in 50 mL of dichloromethane. The reaction mixture was 
stirred for 48 h. The precipitated cyclohexyl urea was removed by filtration, and the 
dichloromethane layer was concentrated and precipitated into diethyl ether twice. The precipitated 
PEG-ECT was washed three times with diethyl ether and dried under vacuum (yield ∼10g). 1H-
NMR (400 MHz CdCl3) revealed 91% substitution of the PEG (data not shown)[28]. 
  RAFT polymerization was used to synthesize a 50:50 butyl methacrylate (BMA; B):2-
(dimethylamino)ethyl methacrylate (DMAEMA; D) copolymer using the PEG-ECT macro-CTA. 
The target degree of polymerization was 160, and the monomer plus CTA was 40% weight per 
volume in dioxane. The polymerization reaction was carried out at 70oC for 24 hours using AIBN 
as the initiator with a 5:1 [CTA]:[Initiator] molar ratio. A monomer feed ratio of 50:50 mol % 
[B]:[D] was used, and a double alumna column was utilized to remove inhibitors from D and B 
monomers prior to polymerization. The reactions were stopped by removal from heat and exposure 
of the polymerization solution to air. The resulting PEGDB polymers were precipitated into a co-
solvent of 90% pentane and 10% diethyl ether. The isolated polymers were vacuum-dried, 
dissolved in water, further purified by dialysis for 24 hours, and lyophilized. Polymers were 
characterized for composition and molecular weight by 1H-NMR spectroscopy (Bruker 400 MHz 
spectrometer equipped with a 9.4 T Oxford magnet). Absolute molecular weight and 
polydispersity of PEGDB polymers was determined using DMF mobile phase gel permeation 
chromatography (GPC, Agilent Technologies, Santa Clara, CA, USA) with inline Agilent 
refractive index and Wyatt miniDAWN TREOS light scattering detectors (Wyatt Technology 
Corp., Santa Barabara, CA). 
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Figure 4.1. Polymer synthesis and characterization. A) PEGDB synthesis scheme. B) Table of 
polymer characterization values. C) Gel permeation chromatography elugram of PEGDB and 5 
kDa PEG-ECT precursor. D) 1H NMR spectrum of PEGDB. [Adapted from Advanced Materials, 
Kelsey R. Beavers et. al., “Porous Silicon and Polymer Nanocomposites for Delivery of Peptide 
Nucleic Acids as Anti-MicroRNA Therapies”, 2016, with permission from John Wiley & Sons] 
 
4.2.4 Nanocomposite formation. The surface of oxidized porous silicon is negatively charged (ζ= 
-20mV) at pH 5.5. At that pH, the PEG-(DMAEMA-co-BMA) is positively charged and largely 
unimeric in solution. Composite particles were formed electrostatically by mixing the two 
components together in de-ionized H2O (pH 5.5) while stirring at RT for 30 min, and the pH was 
subsequently raised to 7.4 using PBS. Coated PSNPs were purified from excess polymer by 
pelleting under centrifugation and removing the supernatant. The relative amounts of PEGDB and 
porous silicon within the composites were quantified by thermal gravimetric analysis (TGA). DLS 
and zeta potential measurements were performed using a Zetasizer NanoZS (Malvern Instruments, 
Worcestershire, UK) to assess changes in particle size and surface charge following polymer 
coating. Lastly, coated particle morphology and elemental composition were characterized by 
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scanning transmission electron microscopy-energy-dispersive X-ray spectrometry (STEM-EDS), 
using a Tecnai Osiris microscope (FEI, Oregon, USA) at a 120 keV accelerating voltage. 
 
4.2.5 Cell culture and in vitro bioactivity. Huh7 cells were cultured in Dubelcco’s modified eagle 
medium supplemented with 10% fetal bovine serum, 2% penicillin/streptomycin, and 2 µg mL-1 
ciprofloxacin. To characterize cellular uptake by confocal microscopy and flow cytometry, Huh7 
cells were treated for 24 h with either free Oregon Green-labeled PNA, or labeled PNA loaded into 
uncoated, partially coated, and fully coated composite PSNPs at a 2 µM PNA dose. 
Huh7-psiCHECK-miR122 luciferase reporter cells were used to assay for anti-miR122 
activity [115]. Cells were seeded at 3,000 cells per well in 96-well black-walled plates and allowed 
to adhere overnight. Cells were then treated in 10% serum for 24 hours at a 2 µM PNA dose. 
Luciferase expression was measured in triplicate using a Dual Luciferase Assay Kit (Promega 
Corporation, Madison, WI) according to the manufacturer’s protocol, and the luminescence was 
recorded an IVIS Lumina III imaging system (Xenogen Corporation, Alameda, CA, USA). 
Relative luciferase expression was calculated as the average ratio of Renilla to firefly luciferase 
expression for each of the three triplicates. Cytotoxicity was calculated from the constitutively 
expressed firefly luciferase luminescence. 
 
4.2.6 Ex vivo hemolysis assay for endosomal escape. Red blood cells (RBCs) were isolated 
from human whole blood according to well-established protocols [116]. RBCs were then incubated 
with either PEGDB (15 μg mL-1 PEGDB) or PSNPs alone (24 μg mL-1 PSNPs), or with composite 
PSNPs (at PEGDB concentrations of 15 μg mL-1) in buffers of pH 7.4, 6.8, 6.2, and 5.6. The pH 
of these buffers was selected to model the extracellular, early endosome, late endosome, and 
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lysosome environments, respectively, encountered along the endolysosomal pathway. After 1 h of 
incubation, RBCs were pelleted by centrifugation, and the supernatant was spectrophotometrically 
analyzed at 451 nm to determine percent hemolysis relative to Triton X-100 detergent. 
 
4.2.7 In vivo pharmacokinetics and biodistribution. CD-1 mice (10 weeks of age; Charles River) 
were injected intravenously into the tail vein with cy5-labeled anti-miR122. Retro-orbital blood 
collection was performed at 5 and 10 min after injection (n=8 per treatment group). In a second 
cohort of mice (n=5 per treatment group), retro-orbital blood collection was performed at 40 and 
80 min after injection. Circulation half-life was determined by measuring Cy5 fluorescence in the 
plasma collected retro-orbitally at 5, 10, 40 and 80 min. The % injected dose in plasma was 
quantified by comparing to a known set of PNA standards in PBS (-/-) over the range of 200% to 
1.5% of the injected dose.   
Mice were euthanized 1 min, 20 min, 160 min, and 24 h after injection and organs were 
harvested for biodistribution analysis. An IVIS Lumina III imaging system was used to quantify 
Cy5 fluorescence in explanted lungs, heart, liver, kidney, and spleen using Living Image 
4.4 quantification software. Pharmacokinetics curves were calculated from each organ by 
integrating each curve from 0–24 h after injection, after baseline subtraction of tissue 
autofluorescence quantified in a saline control group. Bioavailability in major organs was then 
quantified from the average of the areas under the pharmacokinetics curves for each organ. For Si 
content analysis, organs were weighed, homogenized in 3 mL of 20% ethanol in 1N NaOH and 
left for 48 h at room temperature for extraction of Si. Organ homogenate was then centrifuged at 
42000 x g for 25 min. Following centrifugation, 1 mL of the supernatant was removed and diluted 
to 10 mL using de-ionized H2O. Finally, all samples were syringe filtered using a 0.2 µm syringe 
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filter, and Si content was measured using inductively coupled plasma-optical emission 
spectroscopy (ICP-OES) analysis.  
ICP-OES analyses of aqueous / homogenized tissue samples were carried out at Vanderbilt 
University (Department of Civil and Environmental Engineering) using an Agilent ICP Model 
720-ES. A seven-point standard curve was used for an analytical range between approximately 
0.05 mg L-1 and 10 mg L-1 for silicon at a wavelength of 252 nm. Analytical blanks and analytical 
check standards at approximately 0.5 mg L-1 were run and required to be within 15% of the 
specified value. When applicable, analyses were performed on undiluted samples to minimize total 
dissolved loading to the instrument. Samples for analysis were diluted gravimetrically to within 
the targeted analytical range using 2% v/v Optima grade nitric acid (Fisher Scientific) if the 
maximum calibration was exceeded. Yttrium at 1 mg L-1 was used as the internal standard.  
Instrument settings were 1 kW radio frequency (RF) power, 15 mg L-1 argon plasma flow, 0.75 L 
min-1 nebulizer flow, and 5 seconds per replicate read time for 3 replicates. 
 
4.2.8 In vivo miR-122 inhibition and toxicology. Female C57BL/6J mice (12 weeks age, Jackson 
Laboratories) were divided into the following 6 treatment groups (6 mice per group): saline, empty 
composite PSNPs, free anti-miR122 PNA (5 mg kg-1 PNA), PNA loaded into uncoated PSNPs (1 
mg kg-1 PNA), or PNA loaded into composite PSNPs (1 and 5 mg kg-1 PNA). Note that uncoated 
PSNPs were not assessed at the 5 mg kg-1 PNA dose due to acute toxicity caused by particle 
instability—further emphasizing the translational significance of the coating approach.  Mice were 
injected intravenously into the tail vein every other day for 6 days (3 injections). Mice were 
sacrificed on day 6 and the livers were harvested for histology, mRNA, and miRNA analysis.  
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Real-time PCR and individual TaqMan assays were used to quantify levels of miR-122 and 
its mRNA targets. RNA was isolated from liver tissue using Qiazol and miRNeasy Mini Kits 
(Qiagen Venlo, Netherlands) and purified with RNeasy spin column (Qiagen, Venlo, Netherlands). 
The RNA was reverse transcribed using a Taqman microRNA reverse transcription kit based on 
manufactures instructions (Applied Biosystems) and miR-122 was quantified by real-time PCR 
with individual TaqMan miRNA assays (assay ID: 002245, Applied Biosystems). Relative 
quantitative values were determined using the CT method (RQV = 2-(Ct(miRNA)-Ct(U6))) normalized 
to U6. For mRNA quantification, 1 µg of total RNA was reverse transcribed with an iScriptTM 
Reverse Transcription Supermix kit (Bio-Rad Laboratories), and Aldoa, Gys1, MTTP, IL-6, and 
TNA-α were quantified by real-time PCR with TaqMan mRNA assays (assay IDs: 
Mm00833172_g1, Mm01962575_s1, Mm00435015_m1, Mm00446190_m1, and 
Mm00443258_m1, Applied Biosystems) and normalized to peptidylprolyl isomerase A (PPIA). 
Relative quantitative values were determined using the ΔCt method (RQV = 2-(Ct(mRNA)-Ct(PPIA))). 
Plasma collected from cardiac puncture on day 6 was used to analyze mouse plasma 
cholesterol using heparin as an anti-coagulant. Mouse plasma was injected into an ӒKTA Pure 
FPLC using a Superdex 200 increase 10/300 column (Amersham BioSciences). HDL and LDL 
fractions were pooled separately, and then concentrated using Amicon Ultra 15 mL centrifugal 
filters with a MW cut-off of 3 kDa. Total cholesterol in the concentrated HDL or LDL fractions 
was quantified using a Wako Total Cholesterol Kit, as per manufacturer’s instructions, and 
normalized to total protein content using Pierce BCA Protein Assay kit. Results are presented 
relative to cholesterol content in the HDL and LDL fractions of mice injected with saline only. 
Blood collected by cardiac puncture on day 6 was used for toxicological analysis. Serum 
alanine aminotransferase (ALT) levels (marker of liver toxicity) and blood urea nitrogen (BUN) 
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levels (marker of kidney toxicity) were measured using a commercially available Transaminase-
CII kit and Blood Urea Nitrogen-B Test (Wako), respectively. Livers harvested on day 6 were 
formalin fixed and paraffin embedded and stained with H&E, then evaluated by an experienced 
veterinary pathologist blinded to the composition of the groups. There was no evidence of liver 
toxicity observed microscopically.   
Mice were fed a standard chow diet ad libitum and had free access to water. All protocols 
were approved by the Institutional Animal Care and Use Committee of Vanderbilt University and 
done in accordance with the NIH Guide for the Care and Use of Laboratory Animals. 
 
4.3 Results and discussion 
Scheme 4.1 depicts the strategy for PSNP-polymer nanocomposite formation. PSNPs were 
fabricated by ultrasonic fracture of multi-layer porous silicon films and then oxidized in H2O2 at 
115ºC for 4 hours. The PEGDB diblock polymer was synthesized based on previous work by 
Nelson et al., and comprised a 5 kDa PEG block and a BMA/DMAEMA copolymer block with 
approximately 50 mol% of each monomer (Figure 4.1) [28]. In deionized water at pH 5.5, the 
surfaces of oxidized PSNPs are negatively charged (ζ = -20 mV), while the tertiary amines on 
DMAEMA (pKa ~ 6) are predominantly protonated, making PEGDB positively charged and 
unimeric in solution. Composite particles were formed electrostatically by mixing the two 
components together in de-ionized H2O (pH 5.5) while stirring at room temperature for 30 min. 
Coated PSNPs were purified from excess polymer by centrifugally pelleting the PSNP-polymer 
composites and removing the supernatant containing free, unbound polymer. The particle pellet 
was then re-suspended in phosphate buffered saline at physiologic pH (pH 7.4). Exposure of the 
DB polymer block to physiologic pH makes it water-insoluble and triggers polymer self-
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aggregation [28], potentially contributing to hydrophobic stabilization of the surface coating and 
stabilization of the drug loading into the PSNP interior pores. At physiologic pH, addition of 
PEGDB neutralizes negative PSNP surface charge (Scheme 4.1), which is important for systemic 
delivery applications [112]. 
 
 
Scheme 4.1. PSi-polymer nanocomposite fabrication. 1. Electrostatic assembly of PEGDB on the 
negatively charged PSNP surface. 2. Purification of nanocomposites by removal of free PEGDB 
in the supernatant following centrifugation. 3. Buffering the nanoparticle solution to physiologic 
pH increases polymer self-aggregation, potentially contributing to hydrophobic stabilization of the 
surface coating and drug loading into the PSNP interior pores. The bottom panel shows surface 
charge of oxidized PSNPs, PEGDB, and nanocomposites during assembly at pH 5.5, and after 
buffering pH to 7.4. [Adapted from Advanced Materials, Kelsey R. Beavers et. al., “Porous Silicon 
and Polymer Nanocomposites for Delivery of Peptide Nucleic Acids as Anti-MicroRNA 
Therapies”, 2016, with permission from John Wiley & Sons, Ltd.] 
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The ratio of PEGDB polymer to porous silicon was tuned to create a library of 
nanocomposites with varied degrees of polymer surface functionalization (Figure 4.2). Reactant 
weight ratios of 1:5, 1:1, 20:1, and 80:1 (PEGDB:PSNP) yield composite particles containing 12, 
24, 50, and 60 wt% PEGDB, respectively, as determined by thermal gravimetric analysis (TGA) 
(Figure 4.2A). Dynamic light scattering (DLS) measurements reveal that as % PEGDB is 
increased, the PSNP ζ-potential at physiologic pH (7.4) increases and approaches charge neutrality 
(Figure 4.2B). The average hydrodynamic diameter of nanocomposites with up to 24 wt% PEGDB 
is the same as that of uncoated PSNPs (220 nm) (Figure 4.2C). Scanning transmission electron 
microscopy-energy-dispersive X-ray spectrometry (STEM-EDS) analysis of nanocomposites 
confirms that nitrogen and sulfur signals generated by PEGDB co-localize with the Si matrix at 
the nano-scale, supporting our hypothesis that electrostatic interactions facilitate PEGDB 
assembly onto the PSNP surface (Figures 4.2D and 4.3). Spectroscopic evaluation of PSNP 
colloidal stability reveals that coating of PSNPs with PEGDB minimizes particle aggregation and 
precipitation in the presence of salt-containing physiologic buffered saline (Figure 4.2E-F). This 
increased stability can be attributed to PEG’s ability to sterically block surface adsorption of 
proteins and ions, consequently preventing particle aggregation [117]. 
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Figure 4.2. PEGDB effectively coats PSNPs, neutralizing particle surface charge and imparting 
colloidal stability within physiologic buffered saline. Characterization of nanocomposite library 
by A) thermal gravimetric analysis, B) ζ-potential, and C) hydrodynamic size measurements 
acquired in PBS at pH 7.4. D) STEM-EDS elemental mapping of (top) an uncoated PSNP and 
(bottom) composite PSNPs partially coated with PEGDB (24 wt%). The increased strength and 
dispersion of N and S signals in elemental maps of composite particles (bottom) indicates 
successful PEGDB coating of the PSNP matrix. High-angle annular dark-field images are shown 
in the left-most panels. Maps of Si, N, and S are indicated in red, teal, and yellow, respectively. 
Scale bar = 200 nm. E) Particle aggregation and precipitation out of solution, quantified by 
monitoring PSNP absorption at 450 nm over time, shows that fully coated 50% PEGDB 
nanocomposites have increased colloidal stability in PBS. F) Photographs depict PSNP and 
composite colloidal stability in PBS after 60 min. Black arrow indicates precipitated PSNPs. 
[Adapted from Advanced Materials, Kelsey R. Beavers et. al., “Porous Silicon and Polymer 
Nanocomposites for Delivery of Peptide Nucleic Acids as Anti-MicroRNA Therapies”, 2016, with 
permission from John Wiley & Sons, Ltd.] 
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Figure 4.3. STEM-EDS Spectra of oxidized PSNPs and 24% Composite PSNPs shown in Figure 
4.2D. Cu and Al signals are background from the TEM sample holder. Cl, Na, and P signals are 
due to the presence of salts from the PBS buffer in which the particles are fabricated. Si is attributed 
to the porous silicon matrix, and O can be attributed to both the oxide on the PSNP surface as well 
as within the PEG chain. N and S signals are attributed to PEGDB (see Scheme 4.1 and Figure 4.1 
for chemical structure). [Adapted from Advanced Materials, Kelsey R. Beavers et. al., “Porous 
Silicon and Polymer Nanocomposites for Delivery of Peptide Nucleic Acids as Anti-MicroRNA 
Therapies”, 2016, with permission from John Wiley & Sons, Ltd.] 
 
To assess the impact of PEGDB coating density on PSNP uptake and anti-miRNA activity, 
composites with the minimum amount of PEGDB necessary to fully shield the porous silicon 
surface (50 wt%, zeta -3.1 ± 4.0 mV), and composites which were only partially shielded by 
PEGDB (24 wt%, zeta -8.6 ± 3.0 mV) were selected for further in vitro characterization. Cell 
internalization and bioactivity was assessed for a PNA designed to inhibit miR-122, a liver-specific 
miRNA involved in cholesterol biosynthesis. Inhibition of miR-122 is a promising therapeutic 
approach for reducing viremia in patients infected with Hepatitis C, as well as lowering elevated 
cholesterol and triglyceride levels due to hypercholesterolemia [118]. In this study, 
nanocomposites were loaded with anti-miR122 PNA (NH2-ACA AAC ACC ATT GTC ACA CTC 
CA-cys-COOH) by physically adsorbing PNA within oxidized PSNPs, followed by coating with 
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PEGDB as described above. The average PNA loading in the nanoparticle formulations was 
quantified by LCMS to be 34, 22, and 20 nmoles PNA per mg porous silicon (21, 14, and 12 wt% 
PNA) for uncoated, partially coated, and fully coated nanocomposites, respectively (Figure 4.4 
and Table 4.2). To our knowledge, this is the highest reported PNA loading in any nanoparticle 
system, and is 60x higher than what has been reported for anti-miRNA PNA loading in PLGA 
nanoparticles [69], highlighting an important advantage of highly porous PSNPs that do not require 
emulsion fabrication/loading approaches. 
 
Figure 4.4. LCMS chromatographs used to evaluate PNA loading in PSNPs, showing how the 
polymer component of the composite was separated from PNA for drug loading quantification. 
The highlighted peaks were confirmed to be pure anti-miR122 PNA by mass spectrometry. 
[Adapted from Advanced Materials, Kelsey R. Beavers et. al., “Porous Silicon and Polymer 
Nanocomposites for Delivery of Peptide Nucleic Acids as Anti-MicroRNA Therapies”, 2016, with 
permission from John Wiley & Sons, Ltd.] 
 
Table 4.2. PSNP PNA loading calculated from LCMS. 
Sample PNA/PSNP (wt%) 
PNA (nmoles mg-
1) 
Empty Comp 0 0.0 
PNA-Loaded Full Composite 12 19.8 
PNA-Loaded Partial Composite 14 21.9 
PNA-Loaded Uncoated PSNPs 21 34.3 
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Cellular uptake and miR-122 inhibition studies were performed in vitro using Huh7 human 
liver cancer cells (Figure 4.5). Cells were treated for 24 h in Dubelcco’s modified eagle medium 
(DMEM, Gibco Cell Culture, Carlsbad, CA) supplemented with 10% fetal bovine serum, at a 2µM 
dose of PNA. Following treatment, uptake of fluorescently-labeled PNA was quantified by flow 
cytometry and imaged by confocal microscopy. PNA encapsulated in uncoated PSNPs is ~50x 
more efficiently internalized than free PNA (Figure 4.5A). Additionally, PNA uptake decreases 
proportionately with increasing wt% PEGDB (Figure 4.5A and 4.5B). This is likely due to PEG 
shielding on the outer surface of the composite [119]. Importantly, the extent of cytosolic PNA 
delivery increased with increasing PEGDB content, as quantified by co-localization analysis of 
PNA and lysosomes stained with LysoTracker®, 24 h after treatment (Figure 4.5C). This 
enhanced cytosolic PNA delivery can be attributed to both full and partial PEGDB nanocomposites 
possessing pH-dependent, membrane disruptive activity in a relevant endo-lysosomal range, 
whereas uncoated PSNPs do not (Figure 4.5D).  
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Figure 4.5. Coating of PSNPs with PEGDB decreases PNA uptake but increases both endosome 
escape potential and anti-miRNA activity relative to uncoated PSNPs in Huh7 human 
hepatocellular carcinoma cells. PEGDB functionalization decreases cellular uptake, as 
characterized by A) flow cytometry and B) confocal microscopy, 24 h after treatment with Alexa 
Fluor 488-labeled anti-miR122 PNA at a 2 × 10–6 M PNA dose. Top scale bar = 100 μm, bottom 
scale bar = 10 μm. C) PEGDB functionalization increases PNA cytosolic delivery, as shown by 
 54 
colocalization analysis of Alexa Fluor 488-labeled PNA with LysoTracker at 24 h after treatment 
with 2 × 10–6 M PNA. Endosomal entrapment was quantified by calculating the Manders' overlap 
coefficients for green and red pixels, shown at the right as means ± SEM (n ≥ 3 separate images). 
Increased cytosolic delivery observed for composite particles is due to D) the pH dependent 
membrane disruptive function (grey arrow) of PEGDB, as determined by a hemolysis assay. 
Composites did not disrupt erythrocyte membranes at pH 7.4, but produced robust hemolysis at 
pH 6.2, which is representative of late endosomes. E) A firefly luciferase assay reveals that all 
PSNP treatments are non-toxic at a 2 × 10–6 M PNA dose, in contrast to the gold-standard of a 
2′OMe modified RNA delivered using a commercial cationic transfection reagent 
(AMO+Fugene6). F) Therapeutic anti-miR122 activity increases with increasing PEGDB polymer 
functionalization (based on Renilla luciferase readout tied directly to miR-122 inhibition) 24 h 
after treatment, when compared to free, unencapsulated PNA and the control, 2′OMe AMO (p < 
0.05 when compared to *Free PNA or PSNP, **AMO+Fugene6, and ***Partial Comp). [Adapted 
from Advanced Materials, Kelsey R. Beavers et. al., “Porous Silicon and Polymer Nanocomposites 
for Delivery of Peptide Nucleic Acids as Anti-MicroRNA Therapies”, 2016, with permission from 
John Wiley & Sons, Ltd.] 
 
Anti-miR122 activity was quantified using Huh7 cells stably transfected with a Renilla 
luciferase sensor for endogenous miR-122 [115]. Inhibition of miR-122 in these cells causes an 
increase in luciferase signal. Both anti-miRNA activity and cytotoxicity were benchmarked against 
the anti-miRNA oligonucleotide (AMO) agent used in development and validation of this 
luciferase reporter cell line: 2’OMe PS modified RNA delivered with the cationic commercial 
transfection reagent, FuGENE® 6. All PSNP treatments cause significantly less cytotoxicity than 
FuGENE® 6 (Figure 4.5E), which is too toxic (and colloidally instable) for in vivo translation. 
Although cell uptake was reduced (Figure 4.5A), anti-miR122 activity was 6-fold and 10-fold 
greater than uncoated PSNPs for the partial and fully coated nanocomposites, respectively (Figure 
4.5F). Furthermore, fully coated nanocomposite PSNPs demonstrate 2.3 fold higher miR-122 
inhibition relative to the AMO standard. Taken together, these data suggest that fully coated 
composites are non-toxic and have potent anti-miRNA activity due to increased delivery of PNA 
to the cytosol, where miR-122 is located. 
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To evaluate whether nanocomposites improve the blood circulation half-life and miRNA 
inhibitory bioactivity of PNA in vivo, CD-1 mice (10 weeks of age, Charles River) were injected 
intravenously via the tail vein with 1 mg kg-1 cy5-labeled anti-miR122 PNA (free, loaded into 
uncoated PSNPS or fully coated nanocomposites) (Figure 4.6). Blood samples were collected 5, 
10, 40, and 80 minutes after injection, and circulation half-life was determined based on the 
quantity of PNA in the plasma collected at each time point (Figure 4.6A). Uncoated PSNPs 
extended the circulation half-life of free PNA from <1 min to ~30min, and addition of the PEGDB 
coating to PSNPs more than doubled the half-life to nearly 70 min. As a result of increased 
circulation time, encapsulation of PNA anti-miR122 in nanocomposites increased its 
bioavailability by 73x, as quantified by the area under the curve (AUC).  
The organ biodistribution of PNA and the PSNP carrier were determined by excising the 
heart, lungs, liver, spleen, and kidneys 160 min after injection. Investigations into novel nucleic 
acid delivery systems typically track the fluorescently-labeled nucleic acid without tracking the 
carrier system. An advantage of using porous silicon nanocarriers is that their biodistribution can 
be tracked label-free using inductively coupled plasma-optical emission spectroscopy (ICP-OES). 
Figure 4.6B compares the biodistribution of fluorescently labeled PNA cargo with that of Si from 
the porous silicon nanocarriers. The biodistribution of Si is similar to that of the PNA for both 
uncoated and composite nanoparticles, suggesting that the PNA cargo may remain stably 
associated with the porous silicon carrier in the circulation and during initial tissue biodistribution. 
It is well established that nanoparticles larger than 200 nm in size are preferentially sequestered in 
the liver sinusoidal endothelium [120]. Due to their size, PSNPs and nanocomposites increased 
PNA delivery to the liver (where hepatocytes containing the target miR-122 are located) by ~16%, 
and reduced the amount of PNA in the kidneys by ~33% when compared with free PNA (Figure 
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4.6B). ICP-OES analysis reveals a ~20% increase in Si in the spleen of composite particles when 
compared to uncoated particles. The spleen, like the liver, is known to play a primary role in 
nanoparticle clearance. Additionally, PEGDB coated nanoparticles display 12% less Si 
accumulation in lungs compared with uncoated PSNPs 160 min after injection, and 29% less lung 
bioavailability over 24 h (Figures 4.6 and 4.7), corroborating in vitro data (Figure 4.2 E-F) that 
PEGDB reduces flocculation which causes accumulation in the lungs [121]. A final observation is 
that while ~20% of all PNA is found in the kidneys, no more than 6% of all measured Si is detected 
in the kidneys by ICP-OES.  Free PNA pharmacokinetics data suggests that the kidney is a 
preferential route of clearance, which is anticipated based on the small size of free PNA, below 
the renal cutoff.  The difference in PNA and Si content suggests that a portion of the PNA cargo 
released from the PSNP carriers in circulation due to the noncovalent PNA loading mechanism.  
We next tested whether PSNP-polymer nanocomposites improve PNA bioactivity (miR-
122 inhibition) in the liver. Female C57BL/6J mice (12 weeks of age, Jackson Laboratories) were 
treated with either saline, free anti-miR122 PNA (5 mg kg-1 PNA), PNA loaded into composite 
PSNPs (5 mg kg-1 PNA, 42 mg kg-1 PSNP composite), or an empty composite vehicle control (42 
mg kg-1 PSNP composite). Importantly, the uncoated nanoparticles demonstrated poor colloidal 
stability in physiologic solutions (Figure 4.2E-F). We were unable to safely inject uncoated 
PSNPs intravenously at 5 mg kg-1 PNA dose for this study due to acute mortality. The acute 
toxicity for the 5 mg kg-1 uncoated treatment group could be due to particle aggregation resulting 
in blockage of pulmonary capillaries. This result highlights the importance of the colloidal 
stabilization of PSNPs by PEGDB, which significantly reduced particle accumulation in the lungs 
(Figures 4.6C and 4.7). 
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Figure 4.6. PSNP-polymer nanocomposites increase PNA blood circulation half-life, 
bioavailability, and anti-miRNA activity in vivo. A) Blood pharmacokinetics curves generated 
using cy5-labeled PNA show that PSNP composites increase circulation half-life of PNA when 
delivered I.V. through the tail vein of mice at a 1 mg kg−1dose (n = 8 per group for 0–20 min, n = 
5 per group for 40–80 min). B) In vivo biodistribution of cy5-PNA cargo and Si from the PSNP 
carriers was analyzed by fluorescent imaging and ICP-OES, respectively. PNA and Si organ 
distributions 160 min after injection show that PSNPs increase PNA accumulation in the liver and 
decrease uptake in the kidneys. C) Quantification of bioavailability in blood, liver, and lungs 
demonstrates that PEGDB functionalization improves blood circulation stability and decreases 
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accumulation of particles in the lungs. D–H) In vivo miR-122 inhibition studies following 
injection of a 5 mg kg–1 dose of PNA, every other day for 6 d (n = 6 mice per group). D) Livers 
were evaluated by an experienced veterinary pathologist blinded to the composition of the groups, 
who noted no evidence of liver toxicity observed microscopically (representative image shown,n = 
6 mice per group). E) Nanocomposite delivery of anti-miR122 PNA D) significantly inhibits miR-
122 and F) modulates the expression of miR-122 direct target genes, Aldoa and Gys1, in addition 
to the indirect target gene MTTP (Grey line indicates saline control). Cholesterol measurements 
on G) HDL and H) LDL fractions separated by fast protein liquid chromatography (FPLC) from 
plasma collected on day 6 reveals decreased cholesterol in HDL following treatment with 
nanocomposites loaded with anti-miR122 PNA. (*, **, and *** indicate p < 0.05 when compared 
to free PNA, PSNPs, and empty vehicle control, respectively). [Adapted from Advanced Materials, 
Kelsey R. Beavers et. al., “Porous Silicon and Polymer Nanocomposites for Delivery of Peptide 
Nucleic Acids as Anti-MicroRNA Therapies”, 2016, with permission from John Wiley & Sons.] 
 
 
Figure 4.7. Biodistribution of cy5-PNA in the major organs as a function of time, following a 
single intravenous injection of A) 1 mg kg-1 free PNA, B) 1 mg kg-1 PNA loaded into uncoated 
PSNPs, and C) 1 mg kg-1 PNA loaded into composite nanoparticles (n > 3 mice/group). A non-
linear, one-phase exponential decay model was used to generate pharmacokinetics curves for each 
data set (average curves shown as solid lines in charts A-C). D) PNA bioavailability was then 
characterized by calculating the area under the curves from 0-24 h. (* and ** indicate p<0.05 when 
compared to free PNA and PSNPs, respectively). [Adapted from Advanced Materials, Kelsey R. 
Beavers et. al., “Porous Silicon and Polymer Nanocomposites for Delivery of Peptide Nucleic 
Acids as Anti-MicroRNA Therapies”, 2016, with permission from John Wiley & Sons, Ltd.] 
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Mice were injected intravenously into the tail vein every other day for 6 days (3 injections), 
then sacrificed, and their livers were harvested for mRNA, and miRNA analysis (Figure 4.6 D-
F). There were no overt signs of toxicity for the composite nanoparticles, and levels of blood urea 
nitrogen (BUN) and alanine aminotransferase (ALT) measured on day 6 serum samples collected 
at the time of mouse sacrifice suggested that treatment did not cause kidney or liver toxicity relative 
to control treatment groups (Figures 4.6D and 4.8). Real-time PCR for miR-122 expression shows 
that composite PSNPs inhibited miR-122 by 46% relative to the empty vehicle control (Figure 
4.6E).  Additionally, treatment with nanocomposites caused an ~50% increase in expression of 
both Aldolase A (Aldoa) and Glycogen Synthase 1 (Gys1), validated miR-122 gene targets that 
encode for proteins which degrade cholesterol and synthesize glycogen, respectively (Figure 
4.6F). Furthermore, expression of Microsomal Triglyceride Transfer Protein (MTTP), an indirect 
target of miR-122 known to be down-regulated upon miR-122 inhibition, was decreased by 36% 
relative to the vehicle control (Figure 4.6F) [122].  Finally, the functional impact of miR-122 
inhibition was assessed by analyzing the cholesterol content in the high-density lipoprotein (HDL) 
and low-density lipoprotein (LDL) serum fractions collected from mice on day 6 (Figure 4.6G-
H). Consistent with the known function of miR-122 [118], inhibition of miR-122 using PNA-
loaded nanocomposites caused an ~20% decrease in HDL cholesterol. This is, to our knowledge, 
the first demonstration of in vivo PNA-mediated miR-122 inhibition, and the nanocomposite PNA 
delivery technology exhibits miR-122 inhibition at 16x lower dose than RNA-based anti-miR122 
antagomirs [42], and 2.5x lower dose than a  2-O-methoxyethyl phosphorothioate AMOs [118]. 
Systemic and intracellular pharmacokinetics limitations are the biggest challenges facing 
PNA-based therapeutics. Our in vitro and in vivo results confirm that free PNA suffers both from 
poor cellular internalization, poor systemic pharmacokinetics, and lack of intracellular 
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bioavailability. Our in vitro data support the importance of overcoming intracellular delivery 
barriers. Despite a significantly higher level of cell uptake, the uncoated PSNP carriers produced 
significantly lower miRNA inhibition than composite particles with active endosomal escape 
capacity (Figure 4.4). Furthermore, the nanocomposite showed superior blood circulation time 
and systemic bioavailability (Figure 4.6) due to particle colloidal stabilization with PEG.  Finally, 
PEGDB polymer coating enabled I.V. delivery of a 5x higher PNA dose than uncoated PSNPs. At 
this PNA dose (5 mg kg-1), composite particles successfully inhibited miR-122 in the liver, de-
repressed the miR-122 target gene, Aldoa, and lowered plasma cholesterol levels. Thus, the 
nanocomposite design was strategically crafted to overcome both the key systemic and 
intracellular delivery barriers facing PNA.  
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Figure 4.8. Toxicology assessments in mice at day 6 of in vivo miRNA inhibition study (following 
treatment on days 1, 3, 5 with 5 mg kg-1 PNA or equivalent unloaded carrier) showed no signs of 
toxicity from composite nanoparticles. A) Liver toxicity was evaluated by monitoring alanine 
aminotransferase (ALT) levels in blood, and B) kidney toxicity was evaluated by quantifying 
blood urea nitrogen levels.  The healthy range is indicated by the gold shaded region in each graph. 
C) No significant change in body weight was measured 48 h after treatment with 5 mg kg-1 PNA 
treatment, or the corresponding empty vehicle control. Additionally, PCR analysis of livers on day 
6 revealed no change in the expression of D) IL-6 inflammatory cytokines, whereas levels of the 
cytokine E) TNF-alpha were increased for nanocomposite treatment groups. (*p<0.05 compared 
to saline) [Adapted from Advanced Materials, Kelsey R. Beavers et. al., “Porous Silicon and 
Polymer Nanocomposites for Delivery of Peptide Nucleic Acids as Anti-MicroRNA Therapies”, 
2016, with permission from John Wiley & Sons, Ltd.] 
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4.4 Conclusion 
This is, to our knowledge, only the fourth report of in vivo miRNA silencing with a PNA 
therapeutic [66, 68, 69], and the first report of an endosomolytic PNA delivery system. All other 
reports have focused on inhibition of miR-155 for treatment of lymphoma. Initial work by Fabani 
et al. modified PNA with positively-charged lysine residues and saw effective miR-155 inhibition 
at a 50 mg kg-1 PNA dose. In the study by Babar et al., PNA encapsulation into PLGA nanoparticles 
coated with a cell-penetrating peptide (0.35 wt% PNA loading) reduced the effective PNA dose to 
1.5 mg kg-1. Cheng et. al. conjugated PNA to a pH-responsive peptide which enables targeted 
delivery of anti-miRNA PNA to the acidic tumor microenvironment. Additionally, the peptide 
utilizes an environmentally-activated non-endocytic cell uptake/membrane transduction 
mechanism. This enabled miR-155 inhibition at a 1 mg kg-1 dose in a mouse model of lymphoma. 
Our non-targeted PNA delivery system beat or approached the level of miRNA inhibitory potency 
of these different targeted delivery approaches, and we hypothesize that this new long-circulating 
nanocomposite can be made more potent by adding targeting ligands, such as GalNAc for 
hepatocyte targeting [123]. 
In summary, this chapter showcases a new nanocomposite PNA delivery vehicle proven to 
overcome both systemic and intracellular delivery barriers. Porous silicon is leveraged as a highly 
porous scaffold amenable to high drug cargo loading; this substrate enables much higher and 
simpler drug loading relative to water in oil in water (W/O/W) emulsion methods commonly 
utilized to load hydrophilic cargo into hydrophobic polymer-based nano- and micro- carriers. 
Furthermore, simple electrostatic assembly was utilized for PSNP surface functionalization with a 
multifunctional polymer that enhances resultant particle colloidal stability, in vivo circulation, and 
intracellular bioavailability. This fabrication process is both facile and rapid, requiring only 
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sequential centrifugal wash steps for composite purification. This approach would also be 
potentially amenable to adaptation to more controlled microfluidic synthesis techniques, such as 
those developed by Santos et. al. [68, 124]. Furthermore, it is well-established that porous silicon 
can host a wide range of cargos [85, 125]. We anticipate that this composite system can facilitate 
the intracellular activity of a broad range of therapeutic and diagnostic payloads. Finally, based on 
its high bioavailability and long blood circulation half-life, this system can also potentially be 
functionalized with active targeting ligands and further tuned to facilitate preferential delivery to 
defined cells and tissues. Thus, PSNP-polymer nanocomposites represent a promising material 
platform with potential high impact in miRNA inhibitory and other biologic nanomedicines. 
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CHAPTER 5 
 
CONCLUSIONS 
5.1 Summary 
Unraveling the secrets of the human genome, researchers have learned more about the role of non-
coding RNAs in disease. The existence of functional non-coding RNAs (like miRNA) now makes 
sense. MiRNAs are well adapted to silence genes because they share the same nucleic acid 
language as their targets. Similarly, it seems that nucleic acid-based drugs are ideal for therapeutic 
silencing of pathological miRNAs. Peptide nucleic acids are excellent miRNA inhibitors, yet they 
have no innate ability to reach miRNA targets in the body. The challenge in developing clinical 
anti-miRNA therapies is therefore a challenge of delivery. This works’ central hypothesis was that 
PNA anti-miRNA activity can be improved by engineering PSNPs to increase PNA blood 
circulation half-life, cellular uptake, and delivery to the cell cytoplasm.  
In Aim 1, strategies for loading PNA into PSi were developed and assessed. Covalent 
attachment of pre-synthesized PNA was found to be the least efficient method of drug loading. 
Automated in situ synthesis of PNA from PSi was developed as an alternative, highly efficient 
covalent drug-loading strategy. Physical adsorption of PNA was an equally efficient drug loading 
strategy (due to PSi’s high internal surface area), but in situ synthesis enabled more control over 
PNA release kinetics. Ultrasonic fracture of perforated PSi multilayers was then show to be an 
effective method for producing PSNPs loaded with PNA. These PSNPs are biocompatible and 
effective at increasing the uptake and activity of anti-miR122 PNA therapeutic in human liver 
cancer cells. 
Aim 2 expanded PNA-loaded PSNP functionality by developing a method to coat these 
particles with PEGDB polymer. Polymer/PSi nanocomposites, formed by simple electrostatic self-
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assembly, possess the pH-responsive endosomal escape properties of PEGDB without sacrificing 
the high PNA loading efficiency of PSi. As a result, these nanocomposites show increased 
cytosolic PNA delivery and improved anti-miRNA activity relative to uncoated PSNPs. Increased 
anti-miRNA activity was seen in spite of the fact that PEGDB decreased PSNP cellular uptake. 
This result highlights the therapeutic importance of PEGDB endosomal escape functionality. 
Finally, Aim 3 assessed the activity of PNA-loaded PSNPs targeted against miR-122 in 
vivo. PEGDB functionalization was shown to enhance particle colloidal stability, and the PEG 
block of the polymer made particle surfaces more inert. Consequently, nanocomposites extended 
the blood circulation half-life of intravenously-delivered PNA from <1 min to 70min, increasing 
its bioavailability by 73x. Finally, these nanocomposites were shown to be non-toxic and enable 
PNA-mediated miR-122 inhibition in the liver in vivo, decreasing plasma cholesterol by 20%. The 
culmination of Aims 1 through 3 is a composite nanoparticle proven to overcome both systemic 
and intracellular barriers to the delivery of PNA therapeutics. 
 
5.2 Future directions 
As discussed in Appendix B, the in situ synthesis technique developed as a part of Aim 1 has been 
applied to PSi-based biosensors. These PNA-functionalized biosensors show enhanced stability 
and lifetime over current, DNA-based PSi biosensing technologies. Device stability may be further 
enhanced by alternative linkers for amine functionalization of PSi prior to in situ synthesis. In 
addition, future studies should optimize PNA probe density to strike a balance between device 
accuracy and sensitivity. Ultimately, the PNA/PSi biosensors should be evaluated using 
environments and samples that more accurately reflect the demands of their ultimate application. 
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The nanocomposite developed in Aim 2 showed improved anti-miRNA activity in the liver 
following systemic administration. The application of these nanocomposites should be extended 
to more novel miRNA therapeutic targets in the liver, such as those involved in hyperlipidemia 
and cardiovascular disease. Additionally, the exceptionally long blood circulation half-life of these 
nanocomposites makes them promising candidates for cancer therapy. Future work should 
investigate whether or not the extended circulation half-life increases particle accumulation and 
therapeutic activity in tumors. Finally, the functionality of these nanocomposites may be improved 
by investigating chemistries that improve PEGDB coating stability and/or incorporate specific 
targeting moieties onto the particle surface. 
 
5.3 Conclusion 
The ability to engineer materials at the nanoscale has expanded our toolkit for overcoming 
canonical drug delivery challenges. This work described a highly tunable materials system 
engineered to act as a nanoscale taxi for shuttling therapeutics to their site of action in the body. 
Using similar nanotechnology to inhibit pathological non-coding RNAs may ultimately herald a 
new generation of precision medicine. 
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APPENDIX A 
 
COMPARISON OF PSI OXIDATION METHODS 
 
 Fresh porous silicon is covered with silicon hydride. It develops a thin native oxide upon 
exposure to air. This oxide provides limited resistance against PSNP degradation in biological 
media. Thermal and chemical oxidation methods are commonly used to tune PSNP degradation 
kinetics and slow biodegradation. Figure A.1 shows how increasing the temperature and duration 
of oxidation can be used to slow the degradation of a PSNP in phosphate buffered saline at 37°C. 
I studied the feasibility of thermally oxidizing PSNPs, and found that the particles bonded with 
one another and often remain attached to the walls of their glass container. These results prompted 
investigations into the chemical oxidation of PSi. I chose to study three chemical oxidants: H2O, 
H2O2, and piranha acid.  
 
 
Figure A.1.  PSi particle oxidation alters its degradation rate in biological media. The second row 
demonstrates that increasing oxidation temperature and time increases particle stability. 
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 As PSi oxidizes, its effective refractive index decreases.  This is because the refractive 
index of silicon oxide is ~1.45, whereas the refractive index of silicon is 3.4. Reflectometry was 
therefore used to compare the extent of oxide formation as a function of oxidation method (Figure 
A.2). Five-micron thick PSi films with 70% porosity were fabricated according to the procedure 
reported in Section 3.2.1. These films were then oxidized by the methods outlined in Table A.1. 
The change in PSi optical thickness (∆2nL) before and after oxidation, measured by reflectometry, 
is given in Figure A.2. Of the chemical oxidants studied, high temperature piranha acid was 
determined to form the thickest oxide in the shortest time, but the subsequent time and particle 
loss associated with washing piranha from PSNPs limits its utility. At room temperature, 
submersion into solutions of either H2O or H2O2 for 24 h produce similar changes in optical 
thickness. Increasing the temperature of the H2O2 solution to 115°C shortens the time required to 
form thick oxides on the PSi surface.  H2O2 at 115°C for 4 h can produce a change in optical 
thickness comparable to that of piranha at 115°C for 2h.   
 
Table A.1. List of oxidation methods and corresponding abbreviations. 
Abbreviation Method 
H2O (RT) 24 hr Submersion into H2O at room temperature (RT) for 24 h 
H2O2 (RT) 24 hr Submersion in H2O2 at room temperature (RT) for 24 h 
H2O2 (115°C) 2 hr Submersion in H2O2 at 115°C for 2 h 
H2O2 (115°C) 3 hr Submersion in H2O2 at 115°C for 3 h 
H2O2 (115°C) 4 hr Submersion in H2O2 at 115°C for 4 h 
Piranha (115°C) 2 hr Submersion in Piranha Acid at 115°C for 2 h 
600°C 30 min Oxidation in air at 600°C for 30 min 
800°C 1 hr Oxidation in air at 800°C for 1 h 
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Figure A.2. Change in the value 2nL (where n is the refractive index and L is the thickness of the 
film) determined by reflectance measurements after oxidation. 
 
 Decreasing optical thickness can be caused by PSi dissolution, rather than oxidation.  To 
test for oxide formation, films were analyzed by Fourier transform infrared spectroscopy (FTIR). 
Figure A.3 shows a comparison of the FTIR spectra of PSi films left to form a native oxide layer 
in air for 24 h, submerged in H2O for 24 h, chemically oxidized with H2O2 at 115°C for 4 h, or 
thermally oxidized in air at 600°C for 30 min. PSi samples exposed to either water or air at room 
temperature show strong absorption peaks due to Si-Si vibrations, Si-H bending, and Si-H2 
wagging near 615 cm-1. Both also exhibit absorption peaks due to Si-H2 scissor bending and Si-H 
stretching at 900 and 2150 cm-1[126]. The lack of oxide bonds on the surface of the water oxidized 
sample suggests hydrolytic degradation as the primary reason for the previously observed decrease 
in optical thickness (Figure A.2). In contrast, the PSi films oxidized either thermally in air or 
chemically with H2O2 show a marked decrease in absorbance due to Si-Si, Si-H, and Si-H2 bonds.  
Instead, strong absorption peaks from SiOx, Ox-Si-H, and Si-OH bonds appear at 1100, 2245, and 
3740 cm-1[127]. Pore morphology after high temperature H2O2 oxidation, characterized by 
scanning electron microscopy (SEM), is similar to that of un-oxidized PSi (Figure A.4). This 
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result, combined with FTIR and reflectometry data, suggests that high temperature H2O2 oxidation 
causes formation of an oxide similar to that formed thermally in air at 600°C for 30 min. Unlike 
water oxidation, H2O2 oxidation does not cause significant hydrolytic degradation. 
 
 
Figure A.3. FTIR spectra of PSi films subjected to various oxidation treatments. 
 
 As discussed previously, formation of a thick oxide layer should slow PSi aqueous 
dissolution. PSi pore morphology was evaluated before and after exposure to deionized water at 
80°C for 1 h (Figure A.4). PSi films oxidized in H2O2 show less dissolution and pore widening 
than unoxidized PSi. In conclusion, chemical oxidation of PSNPs at 115°C for 4 h is an effective 
means of slowing PSi hydrolytic degradation and functionalizing the surface with hydroxide 
species that can be used for subsequent chemical modification. 
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Figure A.4. SEM micrographs of PSi after to exposure to deionized water at 80°C for 1 h shows 
that high temperature H2O2 oxidation slows hydrolytic PSi degradation. 
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APPENDIX B 
 
IN SITU SYNTHESIS OF PNA IN PSI FOR BIOSENSING 
 
A biosensor is a device that detects an analyte of interest (such as glucose or viral RNA) 
using a biological probe (such as a protein or DNA) [128].  Biosensors that detect nucleic acids 
have many applications, including disease diagnosis and detection of food-borne pathogens [129]. 
To ensure both sensitivity and accuracy, these applications require stable integration of probes 
onto analytical devices capable of reproducible and sensitive hybridization detection [130, 131]. 
While nanostructured surfaces like PSi possess advantageous properties for enhancing detection 
signals [132], a major challenge facing nanostructured biosensors is sensor stability [133].  Our 
group recently showed that functionalization of PSi biosensors with negatively charged DNA 
molecules induces PSi corrosion that masks binding events with target molecules [134]. This 
corrosion is completely mitigated when DNA probes are replaced by charge-neutral PNA probes 
[134]. In addition to their neutral charge, PNA offer several advantages over DNA and RNA 
biosensor probes: greater binding affinity for complementary oligos [12] and the ability to form 
hybrids with less sensitivity to changes in temperature, pH, and ionic strength [11, 51]. Chapter 3 
introduced in situ PNA synthesis as an effective means for efficient, covalent attachment of PNA 
to PSi surfaces. This appendix describes the use of in situ synthesis to functionalize PSi biosensors.  
The first PSi biosensor evaluated in this study is a simple, single-layer, Fabry-Perot 
interferometer. In these devices, hybridization is detected optically as an increase in optical 
thickness following capture of the target nucleic acid by probe molecules in the pores. In situ 
synthesis and physical adsorption on PSi yield similar levels of PNA functionalization (Chapter 
3).  However, in situ synthesis results in covalent attachment of PNA to the PSi silicon surface. 
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We therefore hypothesized that in situ synthesis would yield a more stable PSi biosensor. For this 
investigation, a model 16-mer probe PNA (NH2-TAG CTA TGG TCC TCG T-COOH) was 
synthesized from a 10µm thick single-layer PSi film. The stability of a biosensor functionalized 
with in situ synthesized PNA was compared against that of a separate device functionalized with 
physically adsorbed PNA of the same sequence. Stability was evaluated by soaking PNA 
functionalized biosensors in deionized water at room temperature for 1 h (Figure B.1.). A decrease 
in optical thickness following the 1 h presoak indicates instability of the sensor surface, which was 
apparent only for the physically adsorbed PNA samples (Figure B.1.A.). This results supports the 
hypothesis that covalent attachment of PNA probes increases the stability of PSi biosensors. 
 Biosensor selectivity was evaluated by incubating with 10 µM solutions containing either 
a 100% complementary DNA target (NH2-A CGA GGA CCA TAG CTA-COOH) or a 100% 
mismatch DNA sequence (NH2-G GTT TCT GAT GCT GAC-COOH) in HEPES buffer. As 
shown in Figure B.1.B., negligible change in optical thickness was observed following in situ 
synthesized device incubation with either the mismatch DNA sequence or buffer alone, suggesting 
that there are no significant non-specific binding events. In contrast, incubation with the 
complementary DNA target significantly increased the film optical thickness, confirming that 
DNA hybridized to the complementary PNA probe molecules (Figure B.1.B). As a result of its 
instability, the physically adsorbed device showed significantly less detection sensitivity than the 
in situ synthesized device (Figure B.1.A). In situ synthesis is, therefore, a more promising means 
of functionalizing PSi biosensors.  
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Figure B.1. Stability and selectivity assays on single-layer Fabry-Perot PSi interferometers 
functionalized with either A) physically adsorped, or B) in situ synthesized 16-mer probe PNA. 
[Adapted from Bioconjugate Chemistry, 25 (7), Kelsey R. Beavers et. al., “In Situ Synthesis of 
Peptide Nucleic Acids in Porous Silicon for Drug Delivery and Biosensing”, 1192-1197, 2014, 
with permission from the American Chemical Society.] 
 
We next evaluated the applicability of in situ PNA synthesis for more sophisticated PSi 
biosensors. A PSi waveguide is a device that consists of two PSi layers: a low porosity (high 
refractive index) layer, and a high porosity (low refractive index) layer [135]. A prism can be used 
to evanescently couple light into the waveguide. The angle at which light couples into the 
waveguide can be used to monitor hybridization because this resonance angle is dependent on the 
effective refractive index of the waveguide [135]. Figure B.2. shows that a PSi waveguide 
functionalized by in situ PNA synthesis can selectively detect target nucleic acids via an increase 
in resonance angle. While this result demonstrates selectivity for a 100% complementary sequence 
relative to a 100% mismatched sequence, the failure sequences resulting from in situ synthesis 
(discussed in section 3.3) may result in false positives due to binding of incomplete probe 
sequences to partially complimentary targets. 
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Figure B.2. Optical thickness-based hybridization assay using in situ synthesized 16-mer PNA on 
a PSi waveguide. Sequence-specific hybridization (indicated by a significant increase in resonance 
angle) was detected with a complementary target sequence but not with a mismatched control 
sequence. (*p<0.0005). 
 
As discussed in Section 3.3, we hypothesize that incomplete PNA sequences are the result 
of steric crowing in smaller pores. Findings from studies done on DNA synthesis in controlled 
pore glass can be applied to estimate the minimum pore diameter (Dmin) required for efficient PNA 
synthesis in PSi (Equation B.1) [136]. In this equation, the length of the PNA oligo (Loligo) is 
estimated by multiplying the number of bases (n) with the average length of a single PNA 
monomer (Lbase).  This value is then added with the length of the linker molecule (Llinker) and 
multiplied by 4, since previous studies have estimated that oligo yield significantly decreases when 
pore size is less than four times the oligo length [136]. The molecular length of APTES is 
approximately 8 Å [101], and each PNA base extends a growing oligo by approximately 3.5 Å 
[102]. Thus, Dmin for a 16-mer PNA is estimated to be 26 nm. The problem of failure sequences is 
therefore exacerbated for PSi devices with large populations of pores less than 25 nm in diameter. 
 
𝐷min=(𝐿𝑜𝑙𝑖𝑔𝑜+𝐿𝑙𝑖𝑛𝑘𝑒𝑟)×4=(𝑛𝐿𝑏𝑎𝑠𝑒+𝐿𝑙𝑖𝑛𝑘𝑒𝑟)×4   Equation B.1 
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Figure B.3. compares the structures and synthesis coupling efficiencies of two PSi 
biosensor designs: a 10 um-thick Fabry-Perot interferometer, and a 200 nm-thick waveguide. The 
average pore size for the interferometer is 25 nm, whereas the average pore size for the waveguide 
is layer-dependent (Figure B.3.A).  The low porosity layer of the waveguide has the smallest pore 
sizes (15 - 25 nm in diameter). Changes in optical thickness reflect the efficiency of PNA monomer 
coupling during synthesis. Decreasing changes in optical thickness with increasing PNA length 
correspond to imperfect coupling and creation of failure sequences. The coupling of nucleobases 
10-16 is less efficient for the PSi waveguide when compared to the interferometer. This finding, 
together with the results of the pore widening study presented in Figure 3.6, supports our 
hypothesis that synthesis efficiency is dependent on pore diameter rather than pore length. 
 
 
Figure B.3. Comparison of in situ PNA synthesis a PSi interferometer and waveguide. A) Cartoon 
schematics of the structures of a PSi interferometer and waveguide. B) Optical thickness profiles 
during PNA synthesis on the two different devices. Dashed lines indicate linear regression fits for 
the interferometer (black) and waveguide (red). Note that optical thickness is normalized to the 
optical thickness of the APTES-coated film for comparison. 
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Pore widening was previously shown to improve coupling efficiency (Chapter 3). My 
hypothesis is that this improved efficiency is due to decreased steric crowding of growing PNA 
oligos. I therefore anticipate that coupling efficiency can also be improved by decreasing the 
density of reactive sites for PNA synthesis on the PSi surface.  To test this hypothesis, I first 
fabricated PSi films with the interferometer design outlined in Figure B.3.A. These films were 
then silanized with APTES using the same protocol as all previous studies (1% v/v APTES in 
Toluene incubated for 10 min at room temperature). The optical thickness of all of the silanized 
films was measured. A Kaiser test for free terminal amines [137] was then used to quantify the 
amount of grafted APTES on a single PSi sample. Using this information, I set up a series of 
reactions in which I varied the molar ratio of the nucleobase Adenine (“A”) to APTES (Table 
B.1). After coupling, any unreacted amines were capped by acetylation with acetic anhydride.  
 
Table B.1. Molar ratios of Adenine:APTES used in capping study for in situ PNA synthesis. 
Treatment # Molar ratio of A:APTES 
I 4:1 
II 0.75:1 
III 0.5:1 
IV 0.25:1 
V 0:1 
 
The effect of this capping procedure on the density of grafted PNA monomers was 
evaluated by reflectometry, optical absorbance of the fulvene-piperidine, and Kaiser tests. Figure 
B.4 shows that the density of grated PNA monomers on the surface of a PSi biosensor can be tuned 
by varying the molar ratio of the first base to free amines, then capping unreacted amines.  Using 
this capping procedure, a fresh PSi film was partially reacted with the first nucleobase such that 
the number of growing oligo chains took up only 20% of the free amines initially available on the 
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surface. Anti-miR122 PNA (23 nucleobases in length) was then synthesized from the surface of 
the capped device. Figure B.5. compares changes in optical thickness observed during synthesis 
with and without partial reaction and capping to decrease PNA surface density. As expected, the 
total shift in optical thickness is lower for the capped device. However, the optical thickness profile 
on the capped device is more linear than that of the device without capping. This suggests that 
decreasing the surface density of PNA chains during synthesis increases coupling efficiency. 
Future studies will need to verify this result by using LCMS to characterize the relative numbers 
of failure sequences with and without capping. 
 
 
Figure B.4. The A) change in optical thickness, B) absorbance of the fulvene-piperidine released 
by deprotection of grafted monomers, and C) density of grafted monomers all decrease linearly 
after reacting with decreasing molar ratios of A:APTES and capping unreacted amines.  
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Figure B.5. Optical thickness profiles during PNA synthesis with and without capping to decrease 
steric crowding. Dashed lines indicate linear regression fits for synthesis without (black) or with 
(red) partial reaction and capping of free amines at the start of synthesis. Note that optical thickness 
is normalized to the optical thickness of the APTES-coated film for comparison. 
 
In summary, this appendix has discussed the use of in situ synthesis to functionalize PSi 
nucleic acid biosensors. This method of functionalization was shown to increase biosensor stability 
relative to devices functionalized by physical adsorption. Furthermore, sequence-specific 
detection of target nucleic acids was demonstrated for both a PSi interferometer and a PSi 
waveguide. Pore diameter is shown to have an impact on the purity of synthesized PNA probes, 
and two strategies are presented to improve coupling efficiency for longer oligos: pore widening 
and partial reaction of the first base followed by capping. I anticipate that the density of probes on 
the surface will need to be optimized to allow dense coverage of PNA probes, yet leave adequate 
space for target nucleic acid hybridization. Further studies will also be needed to investigate 
whether PSi nucleic acid biosensors based on in situ synthesized PNA have superior selectivity 
and sensitivity relative to traditional DNA probe molecules, as has been suggested for other 
biosensing platforms [130, 131]. 
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APPENDIX C 
 
SHAPE ENGINEERING PSI FOR DRUG DELIVERY 
 
Particle shape is known to significantly impact the mechanism of cellular internalization 
as well as the speed and degree of particle uptake [138-140]. In one example, Gratton et al. 
demonstrated that internalization of cylindrical particles made from cross-linked PEG-based 
hydrogels depends on aspect ratio (AR) [140].  Of all the particles tested, longer cylinders (150 × 
450 nm) were more rapidly internalized by HeLa human cervical carcinoma cells than cubic 
particles of similar volume (200 × 200 nm) or shorter cylinders (100 × 300 nm). One possible 
explanation for shape-dependent differences in nanoparticle uptake is that spherical particles are 
internalized via different pathways [139]. Another possible explanation is that certain aspect ratios 
are better able to activate membrane-associated signaling cascades that initiate vesicle formation 
during endocytosis [141]. 
During endocytosis, macromolecules and solutes are taken into membrane-bound vesicles 
derived from the plasma membrane [142]. Human hepatocarcinoma (liver cancer) cells are 
expected to internalize extracellular milieu by clathrin mediated endocytosis, caveolae mediated 
endocytosis, macropinocytosis, and non-canonical endocytic pathways that are poorly understood 
[142]. Phagocytosis, a mechanism of solid particulate internalization in immune cells, is likely not 
a relevant pathway [142]. Each of these pathways is distinguished from the others by the proteins 
responsible for vesicle formation and the composition of the coating surrounding the endosomal 
vesicle. Particles larger than 200 nm in size (such as the PSNPs investigated in this study), by 
simple size exclusion, are unlikely to fit into clathrin-coated pits and caveolae [142].  Thus, 
macropinocytosis, a high capacity endocytitic mechanism, is the most likely pathway by which 
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PSNPs are taken up into the huh7 liver cancer cells. The quantities of particles internalized by 
macropinosomes has been shown to be dependent on particle shape [141]. We therefore 
investigated whether or not changing the shape of PSNPs affects the route and/or degree of cellular 
uptake, and if this changes the activity of delivered anti-miRNA PNA therapeutics. 
For this investigation, Direct Imprinting of Porous Substrates (DIPS) [25, 143] was used 
to fabricate rectangular PSi nanoparticles with constant volume, but different aspect ratios (1 and 
3.5). A schematic of the DIPS process is shown in Figure A.1. Briefly, PSi films are imprinted 
with a patterned stamp using a hydraulic press (Figure A.1). The stamp pattern and PSi film 
thickness ultimately determine nanoparticle shape and size. Following imprintation, a high-
porosity, sacrificial PSi layer is etched beneath imprinted PSNPs bound to the underlying silicon 
substrate. Particles are then removed from the substrate and suspended in solution by brief 
ultrasonication. Figure A.2 shows successful fabrication of shape-engineered PSNPs. The 
performance of these shape-engineered particles was benchmarked against particles fabricated by 
ultrasonication of multilayered PSi (Section 4.2.1).  
Following fabrication, PSi particles were loaded with anti-miR122 PNA therapeutic and 
fully coated with PEGDB using the methods described in Chapter 4. The bioactivity of PNA 
delivered by these differently-shaped PSi nanoparticles was then characterized in the luciferase-
expressing Huh7 cells used in Chapters 3 and 4. Cells were treated for 24 h with either 1 µM PNA 
loaded into PSNPs, or the equivalent amount of empty PSNPs. The results of this study, shown in 
Figure C.3, indicate that the shape of the PSNP delivery vectors had no effect on the anti-miRNA 
activity of the PNA cargo.  
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Figure C.1. A) Process flow for DIPS particle fabrication. B) Intended morphologies for shape 
engineered PSNPs with aspect ratios of 1 and 3.5.  [Adapted from Nanotechnology, 26 (27), 
Jeremy W. Mares et. al., “Shape-Engineered multifunctional porous silicon nanoparticles by direct 
imprinting”, 2015, with permission from IOP Publishing.] 
 
 
 
 
Figure C.2. Scanning Electron micrographs of shape-engineered PSNPs with intended aspect 
ratios equal to either A) 1, or B) 3.5, fabricated by the DIPS process. 
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Figure C.3. Shape-engineering of PSNP vectors has no effect on anti-miRNA activity in 
luciferase-expressing Huh7 cells (1 µM anti-miR122 PNA dose, 24 h treatment).  “AR1” and 
“AR3.5” stand for PSNPs with aspect ratios of 1 and 3.5, respectively. “Ultra” indicates PSNPs 
which were produced by ultrasonic fracture of multilayer films. “AMO” indicates treatment with 
a 2’OMe-modified RNA AMO delivered with Fugene6 at a 2 µM dose. 
 
 The lack of a shape effect observed in Figure C.3. may be attributed to the size of the 
PSNPs chosen for this study.  As mentioned previously, Huh7 cells are limited to micropinocytosis 
to internalize particles larger than 200 nm in size.  It is possible that PSNP shape will have a greater 
effect on internalization if the largest particle dimension tested is 200 nm. This will be challenging 
because the minimum dimension that can easily be produced by DIPS is ~100 nm. It is also 
possible that shape effects are muted by the addition of the PEGDB polymer coating. Additional 
electron microscopy studies will have to be performed on DIPS particles to determine if they 
maintain their aspect ratios following PNA loading and PEGDB coating. Even if the impact of 
PSNP shape is unapparent in in vitro cell culture models, I anticipate that shape engineered PSNPs 
may improve PNA activity in to context of intravenous or pulmonary PNA delivery in vivo. 
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